Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 97
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alzheimer Dementia Among Individuals With Down Syndrome

  • Rubenstein, Eric
  • Tewolde, Salina
  • Michals, Amy
  • Weuve, Jennifer
  • Fortea, Juan|||0000-0002-1340-638X
  • Fox, Matthew P.
  • Pescador Jimenez, Marcia
  • Scott, Ashley
  • Tripodis, Yorghos
  • Skotko, Brian G.
What is the incidence and prevalence of Alzheimer dementia in patients with Down syndrome using data from the US Medicare and Medicaid? In this cohort study of 132 720 adults with Down syndrome enrolled in Medicaid or Medicare between 2011 to 2019, 23.3% of adults had Alzheimer dementia diagnoses, and the mean age of death was 59.2 years. These findings suggest that Alzheimer dementia is almost universal among people with Down syndrome, and administrative claims data may offer valuable insights into improving care for this diverse population. This cohort study examines the prevalence and incidence of Alzheimer disease among individuals with Down syndrome using US Medicare and Medicaid claims data. With the advancement in administrative data as a research tool and the reliance on public health insurance for individuals with Down syndrome, population-level trends in Alzheimer dementia in this population are beginning to be understood. To comprehensively describe the epidemiology of Alzheimer dementia in adults with Down syndrome in a full US Medicare and Medicaid sample. This cohort study included 132 720 adults aged 18 years or older with Medicaid and/or Medicare claims data with an International Statistical Classification of Diseases and Related Health Problems code for Down syndrome. Data were collected from January 1, 2011, to December 31, 2019, and analyzed from August 2023 to May 2024. The main outcome was prevalence of Alzheimer dementia in each calendar year and during the 9-year period. Alzheimer dementia incidence rates by calendar year and age and stratified for race or ethnicity as well as time to death after Alzheimer dementia diagnosis were also assessed. There were 132 720 unique adults with Down syndrome from 2011 to 2019: 79 578 (53.2%) were male, 17 090 (11.7%) were non-Hispanic Black, 20 777 (15.7%) were Hispanic, 101 120 (68.8%) were non-Hispanic White, and 47 692 (23.3%) had ever had an Alzheimer dementia diagnosis. Incidence was 22.4 cases per 1000 person-years. The probability of an incident Alzheimer dementia diagnosis over 8 years was 0.63 (95% CI, 0.62-0.64) for those entering the study between ages 55 to 64 years. Mean (SD) age at incident diagnosis was 54.5 (7.4) years and median (IQR) age was 54.6 (9.3) years. Mean (SD) age at death among those with Alzheimer dementia was 59.2 (6.9) years (median [IQR], 59.0 [8.0] years). The mean (SD) age at onset for the Hispanic group was 54.2 (9.2) years, 52.4 (7.8) years for the American Indian or Alaska Native group, and 52.8 (8.2) years for the mixed race groups compared with 55.0 (7.8) years for the White non-Hispanic group. For age at death, there were no differences by sex. The mean (SD) age at death was later for the White non-Hispanic group (59.3 [6.8] years) compared with the Hispanic group (58.5 [7.8] years), Native American group (57.8 [7.1] years), and mixed race group (58.2 [7.0] years). In this cohort study of adults with Down syndrome who were enrolled in Medicaid and Medicare, Alzheimer dementia occurred at high rates. Consistency with clinical studies of dementia in Down syndrome supports the use of administrative data in Down syndrome-Alzheimer dementia research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's disease

  • Kac, Przemysław R.|||0000-0001-5083-0924
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Fernández, Susana|||0000-0002-9777-1156
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • González-Ortiz, Fernando
  • Benejam, Bessy|||0000-0002-6789-8615
  • Turton, Michael
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Harrison, Peter
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Fortea, Juan|||0000-0002-1340-638X
  • Blennow, Kaj|||0000-0002-1890-4193
All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate diagnostics, disease monitoring, and treatment. Several genes encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of this biomarker in DSAD and sporadic AD. Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey posthoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes. We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid negative participants. Plasma p-tau212 started increasing approximately when people became amyloid PET-positive. We have confirmed that the levels of plasma p-tau212 are increased in the DS population and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in clinical trials both in sporadic and DSAD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in and

  • Gonzalez, Maria Camila|||0000-0003-1061-4164
  • Oftedal, Linn
  • Lange, Johannes
  • Tovar-Rios, Diego Alejandro
  • Tysnes, Ole-Bjørn
  • Paquet, Claire|||0000-0002-2273-7316
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Rejdak, Konrad
  • Papuc, Ewa
  • Hort, Jakub|||0000-0002-1080-3726
  • Falup-Pecurariu, Cristian
  • Aarsland, Dag|||0000-0001-6314-216X
  • Alves, Guido
  • Maple-Grødem, Jodi
Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bridging perspectives, The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa

  • McGlinchey, E.
  • Ranchod, K.
  • Stroebel, R.
  • Lusizi, B.
  • Galvin, M.
  • Kleinhans, A.V.
  • Fortea, Juan|||0000-0002-1340-638X
  • Hoffman, J.
  • Makanya, S.
INTRODUCTION: Traditional Healing Practitioners (THPs) provide care to the majority of the population in South Africa. Despite their widespread presence, they remain largely excluded from dementia research and policy. This reinforces healthcare inequities and overlooks the realities of communities where THPs provide care. METHODS: This paper explores the role of THPs in dementia care by examining literature in South Africa. It identifies key barriers to collaboration between THPs and medical doctors and discusses pathways for integration. RESULTS: Barriers include epistemological historical marginalization, mutual distrust, fragmented care pathways, and language barriers. These challenges hinder knowledge exchange and joint dementia care strategies. DISCUSSION: Strengthening relationships through structured engagement, bidirectional knowledge exchange, and ethical collaboration could bridge the gap between THPs and Medical Doctors (MDs). A pluralistic, integrated model valuing both systems could lead to more equitable and effective dementia care. Highlights: The majority of people in South Africa engage with Traditional Healing Practitioners (THPs) as part of their healthcare, yet THPs remain largely excluded from dementia research and policy. Barriers to collaboration between THPs and Medical Doctors (MDs) include historical marginalization, mutual distrust, fragmented care pathways, and language differences. Integrating THPs and MDs through structured engagement, bidirectional knowledge exchange, and ethical collaboration could enhance dementia care. Shifting away from the binary opposition of Indigenous Knowledge Systems (IKS) and biomedical approaches toward a more integrated and collaborative model of dementia care could lead to more equitable and effective healthcare. The FUNDISA (Framework for Understanding Neurocognitive Disorders via Indigenous Systems in South Africa) project aims to understand how dementia is conceptualized by THPs and foster collaboration between THPs and MDs to support effective dementia care.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Discrepancies in assessing intellectual disability levels in adults with Down syndrome, Implications for dementia diagnosis

  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Sandkühler, Katja|||0009-0000-7117-2270
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Wlasich, E.
  • Kustermann, J.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fernández, Susana|||0000-0002-9777-1156
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • San Juan, Aida
  • Nübling, G.
  • Wagemann, O.
  • Stockbauer, A.
  • Hassenstab, J.
  • Levin, J.
  • Fortea, Juan|||0000-0002-1340-638X
INTRODUCTION: Cut-offs derived from baseline cognitive assessments, stratified by intellectual disability (ID) level, have been proposed to diagnose symptomatic Alzheimer's disease (AD) in Down syndrome (DS). However, discrepancies in ID classification risk misclassification when applying cut-offs across sites. METHODS: This dual-center cohort study included 673 adults with mild to moderate ID at different AD stages. We assessed ID classification discrepancies across sites and the impact on Cambridge Cognitive Examination for Older Adults with Down's Syndrome (CAMCOG-DS) cut-offs for AD dementia diagnosis derived from receiver operating characteristic analysis. RESULTS: Inter-rater agreement for ID level classification was 95% within sites but 60% between sites. While CAMCOG-DS score distributions in the whole cohort were similar across sites, ID classification discrepancies caused higher cut-offs in Barcelona for mild and moderate ID compared to Munich. Applying site-specific cut-offs to another cohort reduced sensitivity and specificity. DISCUSSION: Standardizing ID classification is critical for generalizable cut-offs to accurately diagnose AD dementia based on neuropsychological assessments in DS. Highlights: CAMCOG-DS cut-offs by intellectual disability level classify dementia in Down syndrome. ID classification discrepancies between sites impact CAMCOG-DS diagnostic cut-offs. Applying site-specific cut-offs to other cohorts reduces sensitivity and specificity. Standardized ID classification is essential for generalizable cognitive cut-offs. Use site-specific cut-offs until ID classification is standardized.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome

  • Sauer, M.
  • Gomes, B.F.
  • Shahrouki, P.
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Camporesi, E.
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Kumar, A.
  • Sharma, M.
  • Singh, S.
  • Brinkmalm, G.
  • Gobom, J.
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Schöll, M.
  • Janelidze, S.
  • Deep, G.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Brinkmalm, A.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Hansson, Oskar|||0000-0001-8467-7286
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Nilsson, J.
INTRODUCTION: Synaptic dysfunction and loss are pathological hallmarks of neurodegenerative diseases. Neuronal pentraxin 2 (NPTX2), a presynaptic protein involved in synaptic plasticity, has been linked to cognitive decline in Alzheimer's disease (AD) and other neurodegenerative disorders. METHODS: We developed and validated a novel single molecule array (Simoa) for NPTX2 in cerebrospinal fluid, which was evaluated in two independent cohorts. RESULTS: CSF NPTX2 concentration was lower (fold change [FC] 0.82, p < 0.01) in AD patients and Down syndrome individuals (FC 0.56, p < 0.001), compared with cognitively unimpaired patients (CU). It was also associated with Mini-Mental State Examination (MMSE) score (β = 2.51, p < 0.001), tau-PET (β = -0.21, p < 0.01), and cortical thickness (β = 0.08, p < 0.001). DISCUSSION: We describe the first assay for NPTX2 on the Simoa platform, where we continue to highlight the valuable addition of NPTX2 to routine diagnostics of suspected cognitive impairment in patients as it associates better with cognition than other, more established AD biomarkers. Highlights: Novel method validated for measuring CSF NPTX2 on semi-automated Simoa platform. Method validated for use in CSF, where it shows a significant decrease in both AD and DS patients. Associated with cognition, neurofibrillary tangles, and cortical thickness in AD patients. Associations with cognition are shown to be stronger than those of pTau and NFL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Down syndrome in Africa, Challenges, opportunities, and future directions

  • McGlinchey, E.
  • Tewolde, S.
  • He, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Mbakile-Mahlanza, L.
  • Tefera, A.
  • Epenge, E.
  • Hassenstab, J.
  • Jäck, A.
  • Ranchod, K.
  • El-Jaafary, S.
  • Levin, J.
  • Salama, M.
  • Rubenstein, E.
  • Akinyemi, R.
  • Akinyemi, T.
  • Farombi, T.
  • Lawlor, B.
  • Ikanga, J.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Stout, S.
  • Balls-Berry, J.
  • Kleinhans, A.V.
  • Maina, R.
  • Merali, Z.
INTRODUCTION: As life expectancy improves for people with Down syndrome (DS) in Africa, the risk of developing DS-associated Alzheimer's disease (DSAD) will rise. There is a pressing need to plan for this emerging challenge, particularly in the context of existing health and social disparities. METHODS: This work emerged from a pan-African collaboration, including discussions at the Brain Ageing and Dementia in Low- and Middle-Income Countries conference held in Nairobi in 2024, where stakeholders identified regional priorities for DS and dementia care. RESULTS: Limited epidemiological, cognitive, biomarker data, delayed diagnoses, and gaps in specialized services may impact access to care. However, innovative solutions, such as mobile biomarker sampling and culturally adapted cognitive assessments, offer promising strategies. DISCUSSION: Integrating global advances in DSAD research with Africa's strengths in community-based care offers opportunities. By prioritizing research, capacity building, and health system integration, this work advocates for the inclusion of DS in Africa's dementia strategies. Highlights: Projected increases in life expectancy for individuals with Down syndrome (DS) in Africa will lead to a substantial rise in DS-associated Alzheimer's disease (DSAD), necessitating urgent planning and response. There is a critical lack of epidemiological, cognitive, and biomarker data on adults with DS in Africa, hindering accurate diagnosis, care planning, and inclusion in global research. Innovative, scalable solutions-such as mobile biomarker sampling and culturally adapted cognitive assessments-offer an opportunity to integrate scientific advances with Africa's strengths in community-based care. Investment in research and capacity building is essential to address current gaps, reduce disparities, and ensure equitable access to emerging diagnostics and treatments for DSAD across the continent.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Aranha, Mateus|||0000-0001-9594-292X
  • Aragón, Irina
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, S.
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Hernandez, Aida S.
Background and Objectives Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. Methods This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. Results We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEe4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. Discussion In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria|||0000-0001-8843-082X
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.|||0000-0001-5949-2191
  • Humphrey, Jack
  • Braun, Alice|||0000-0003-1145-0261
  • Bigdeli, Tim B.|||0000-0003-2215-5946
  • Chatzinakos, Chris
  • Coombes, Brandon J.|||0000-0003-4322-5923
  • Kim, Jaeyoung|||0000-0001-6983-7907
  • Liu, Xiaoxi|||0000-0002-1933-8613
  • Terao, Chikashi|||0000-0002-6452-4095
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Adams, Mark J
  • Adolfsson, Rolf
  • Alda, Martin|||0000-0001-9544-3944
  • Alfredsson, Lars|||0000-0003-1688-6697
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Antoniou, Anastasia
  • Baune, Bernhard T.|||0000-0001-6548-426X
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael|||0000-0002-6442-7754
  • Bosch, Rosa|||0000-0002-7596-183X
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Catts, Stanley
  • Cichon, Sven|||0000-0002-9475-086X
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis|||0000-0001-8531-5623
  • Forstner, Andreas J.
  • Forty, Liz|||0000-0002-4349-8414
  • Frye, Mark
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Gawlik, Micha
  • Gizer, Ian R.
  • Gordon-Smith, Katherine
  • Green, Melissa J.
  • Grigoroiu-Serbanescu, Maria
  • Guzman-Parra, Jose|||0000-0002-1463-6435
  • Hahn, Tim|||0000-0002-8929-4134
  • Henskens, Frans
  • Hillert, Jan|||0000-0002-7386-6732
  • Jablensky, Assen V.
  • Jones, Lisa|||0000-0002-5122-8334
  • Jones, Ian
  • Jonsson, Lina
  • Kelsoe, John R.
  • Kircher, Tilo|||0000-0002-2514-2625
  • Kirov, George|||0000-0002-3427-3950
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Landén, Mikael|||0000-0002-4496-6451
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lenger, Melanie
  • Lissowska, Jolanta
  • Lochner, Christine|||0000-0002-4766-3704
  • Loughland, Carmel
  • MacIntyre, Donald J.|||0000-0001-6963-1335
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Maratou, Eirini
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Mayoral-Cleries, Fermín
  • McElroy, Susan L.
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McIntosh, Andrew M.|||0000-0002-0198-4588
  • McQuillin, Andrew|||0000-0003-1567-2240
  • Michie, Patricia|||0000-0002-4169-8519
  • Mitchell, Philip B.
  • Moutsatsou, Paraskevi
  • Mowry, Bryan J.|||0000-0002-4115-5645
  • Müller-Myhsok, Bertram
  • Myers, Richard M.
  • Nenadić, Igor|||0000-0002-0749-7473
  • Nievergelt, Caroline M.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Nurnberger, John
  • O'Donovan, Michael C.|||0000-0001-7073-2379
  • 'Donovan, Claire O.
  • Ophoff, Roel A.
  • Owen, Michael J.
  • Pantelis, Christos|||0000-0002-9565-0238
  • Pato, Carlos|||0000-0002-5858-266X
  • Pato, Michele T.
  • Patrinos, George P.
  • Pawlak, Joanna M.
  • Perlis, Roy H.|||0000-0002-5862-6757
  • Porichi, Evgenia
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Reif, Andreas|||0000-0002-0992-634X
  • Reininghaus, Eva Z.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Rietschel, Marcella|||0000-0002-5236-6149
  • Schall, Ulrich
  • Schofield, Peter R.|||0000-0003-2967-9662
  • Schulze, Thomas G.
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Serretti, Alessandro
  • Smoller, Jordan W.|||0000-0002-0381-6334
  • Świątkowska, Beata
  • Soler Artigas, María|||0000-0002-3213-1107
  • Stein, Dan J.|||0000-0001-7218-7810
  • Streit, Fabian|||0000-0003-1080-4339
  • Toma, Claudio|||0000-0003-3901-7507
  • Tooney, Paul
  • Vawter, Marquis P.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vincent, John B.
  • Waldman, Irwin D.|||0000-0002-6862-1837
  • Weickert, Cynthia Shannon
  • Weickert, Thomas
  • Witt, Stephanie H.|||0000-0002-1571-1468
  • Hong, Kyung Sue
  • Ikeda, Masashi|||0000-0001-6237-2449
  • Iwata, Nakao|||0000-0003-3189-6076
  • Won, Hong Hee
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Ripke, Stephan|||0000-0003-3622-835X
  • Raj, Towfique|||0000-0002-9355-5704
  • Coleman, Jonathan R.I.
  • Mullins, Niamh
Bipolar disorder is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 bipolar disorder risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci and prioritized 17 likely causal SNPs for bipolar disorder. We mapped these SNPs to genes and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci and results from rare variant exome sequencing in bipolar disorder. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment, including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, FKBP2, RASGRP1, FURIN, FES, MED24 and THRA among others in bipolar disorder. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of bipolar disorder polygenic risk scores across diverse populations and present a high-throughput fine-mapping pipeline.
Repositori Institucional UIB
Publicación Artículo científico (JournalArticle)

Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study

  • Martín-Peláez, Sandra
  • Serra-Majem, Lluis
  • Cano-Ibáñez, Naomi
  • Martínez-González, Miguel Ángel
  • Salas-Salvadó, Jordi
  • Corella, Dolores
  • Lassale, Camille
  • Martínez, Jose Alfredo
  • Alonso-Gómez, Ángel M.
  • Wärnberg, Julia
  • Vioque, Jesús
  • Romaguera, Dora
  • López-Miranda, José
  • Estruch, Ramón
  • Tinahones, Francisco J.
  • Lapetra, José
  • Fernández-Aranda, Fernando
  • Bueno-Cavanillas, Aurora
  • Tur, Josep A.
  • Martín, Vicente
  • Pintó, Xavier
  • Delgado-Rodríguez, Miguel
  • Matía, Pilar
  • Vidal, Josep
  • Vázquez, Clotilde
  • Daimiel, Lidia
  • Ros, Emili
  • Toledo, Estefanía
  • Nishi, Stephanie K.
  • Sorli, Jose V.
  • Malcampo, Mireia
  • Zulet, M. Ángeles
  • Moreno-Rodríguez, Anaí
  • Cueto-Galán, Raquel
  • Vivancos-Aparicio, Diego
  • Colom, Antoni
  • García-Ríos, Antonio
  • Casas, Rosa
  • Bernal-López, M. Rosa
  • Santos-Lozano, Jose Manuel
  • Vázquez, Zenaida
  • Gómez-Martínez, Carlos
  • Ortega-Azorín, Carolina
  • Del Val, Jose Luís
  • Abete, Itziar
  • Goikoetxea-Bahon, Amaia
  • Pascual, Elena
  • Becerra-Tomás, Nerea
  • Chillarón, Juan J.
  • Sánchez-Villegas, Almudena
[eng] Background: Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55–75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial. Methods and findings: Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240–279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively). Conclusions: Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention

  • Soldevila-Domenech, Natalia
  • Fagundo, Ana Beatriz
  • Cuenca Royo, Aida
  • Forcano Gamazo, Laura
  • Gomis-Gonzalez, Maria
  • Boronat, Anna
  • Pastor, Antoni
  • Castañer, Olga
  • Zomeño, M. Dolores
  • Goday, Alberto
  • Dierssen, Mara
  • Baghizadeh Hosseini, Khashayar
  • Ros Rahola, Emilio
  • Corella Piquer, Dolores
  • Martínez-González, Miguel Ángel
  • Salas Salvadó, Jordi
  • Fernández-Aranda, Fernando
  • Fitó Colomer, Montserrat
  • de la Torre, Rafael
Background The Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance. Methods This was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype. Results At baseline, men had better executive function and global cognition than women (the effect size of gender differences was − 0.49, p = 0.015; and − 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen’s d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes. Conclusions The MedDiet improved participants’ cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Relation between length of exposure to epidural analgesia during labour and birth mode

  • Garcia-Lausin, Laura
  • Perez-Botella, Mercedes
  • Duran, Xavier
  • Mamblona-Vicente, Maria Felisa
  • Gutierrez-Martin, Maria Jesus
  • Gómez de Enterria-Cuesta, Eugenia
  • Escuriet, Ramon
Objective: To appraise the relationship between the length of exposure to epidural analgesia and the risk of non-spontaneous birth, and to identify additional risk factors. This study is framed within the MidconBirth project. Study design: A multicentre prospective study was conducted between July 2016 and November 2017 in three maternity hospitals in different Spanish regions. The independent variable of the study was the length of exposure to epidural analgesia, and the dependent variable was the type of birth in women with uncomplicated pregnancies. The data was analyzed separately by parity. A multivariate logistic regression was performed. The odds ratios (OR), using 95% confidence intervals (CI) were constructed. Main outcome measures: During the study period, 807 eligible women gave birth. Non-spontaneous births occurred in 29.37% of the sample, and 75.59% received oxytocin for augmentation of labour. The mean exposure length to epidural analgesia when non-spontaneous birth happened was 8.05 for primiparous and 6.32 for multiparous women (5.98 and 3.37 in spontaneous birth, respectively). A logistic regression showed the length of exposure to epidural during labour was the major predictor for non-spontaneous births in primiparous and multiparous women followed by use of oxytocin (multiparous group). Conclusions: The length of exposure to epidural analgesia during labour is associated with non-spontaneous births in our study. It highlights the need for practice change through the development of clinical guidelines, training programs for professionals and the continuity of midwifery care in order to support women to cope with labour pain using less invasive forms of analgesia. Women also need to be provided with evidence-based information., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Long-term association between water intake and kidney function in a population at high cardiovascular risk

  • Paz Graniel, Indira
  • Valle Hita, Cristina
  • Babio, Nancy
  • Serra Majem, Lluís
  • Vioque, Jesús
  • Zomeño, M. Dolores
  • Corella Piquer, Dolores
  • Pintó Sala, Xavier
  • Cano-Ibáñez, Naomi
  • Tur, Josep A.
  • Cuadrado-Soto, Esther
  • Martínez, José Alfredo
  • Díaz López, Andrés
  • Torres-Collado, Laura
  • Goday, Alberto
  • Fernández-Carrión, Rebeca
  • Nissenshon, Mariela
  • Riera-Mestre, Antoni
  • Garrido-Garrido, Eva
  • Bouzas, Cristina
  • Abete, Itziar
  • Daimiel, Lidia
  • Cornejo-Pareja, Isabel María
  • Vázquez Ruiz, Zenaida
  • Khoury, Nadine
  • Pérez-Vega, Karla Alejandra
  • Salas Salvadó, Jordi
Objectives The evidence on water intake in the prevention of kidney function decline is scarce at population level in well-being individuals at high cardiovascular risk. Therefore, we aimed to longitudinally evaluate the associations between total water intake and subtypes and kidney function, through estimated-Glomerular Filtration Rate (eGFR). Methods Three-year prospective analysis conducted in 1986 older adults (aged 55–75 year) with overweight/obesity and metabolic syndrome from the PREDIMED-Plus study. Water intake was assessed using validated beverage and food frequency questionnaires. Serum creatinine-based eGFR (SCr-based eGFR; ml/min/1.73 m2) was estimated using the CKD-EPI equation at baseline, one-year and 3-years of follow-up. Mixed-effects linear regression models were fitted to evaluate the associations between baseline total water intake and subtypes, and SCr-based eGFR over 3-years of follow-up. Results Participants in the highest baseline tertile of total water intake, plain water and water from all fluids showed a lower decrease in SCr-based eGFR after 3-years of follow-up, compared to those in the lowest tertile. Participants with the highest tap water consumption showed a lower SCr-based eGFR decline after 1-year and 3-years of follow-up, in comparerd to participants in the lowest intake category (T3 vs. T1: β: 1.4 ml/min/1.73 m2; 95%CI: 0.5–2.3, β: 1.0; 95%CI: 0.1–2.0, respectively). Conclusions Plain water rather than other water sources, and especially tap water, was associated with lower kidney function decline assessed through eGFR over 3-years of follow-up, in older individuals at high cardiovascular risk., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder

  • Richarte Fernández, Vanesa
  • Sanchez Mora, Cristina P
  • Corrales De la Cruz, Montserrat
  • Fadeuilhe Grau, Christian
  • Vilar Ribo, Laura
  • Arribas Garcia, Lorena
  • Garcia Gea, Estela
  • Rosales Ortiz, Silvia Karina
  • Soler Artigas, Maria
  • Ribases Haro, Marta
  • Ramos-Quiroga, Josep Antoni
TDAH; Comunitat científica, TDAH; Comunidad científica, ADHD; Scientific community, Compelling evidence supports alterations in gut microbial diversity, bacterial composition, and/or relative abundance of several bacterial taxa in attention-deficit/hyperactivity disorder (ADHD). However, findings for ADHD are inconsistent among studies, and specific gut microbiome signatures for the disorder remain unknown. Given that previous studies have mainly focused on the pediatric form of the disorder and involved small sample sizes, we conducted the largest study to date to compare the gastrointestinal microbiome composition in 100 medication-naïve adults with ADHD and 100 sex-matched healthy controls. We found evidence that ADHD subjects have differences in the relative abundance of several microbial taxa. At the family level, our data support a lower relative abundance of Gracilibacteraceae and higher levels of Selenomonadaceae and Veillonellaceae in adults with ADHD. In addition, the ADHD group showed higher levels of Dialister and Megamonas and lower abundance of Anaerotaenia and Gracilibacter at the genus level. All four selected genera explained 15% of the variance of ADHD, and this microbial signature achieved an overall sensitivity of 74% and a specificity of 71% for distinguishing between ADHD patients and healthy controls. We also tested whether the selected genera correlate with age, body mass index (BMI), or scores of the ADHD rating scale but found no evidence of correlation between genera relative abundance and any of the selected traits. These results are in line with recent studies supporting gut microbiome alterations in neurodevelopment disorders, but further studies are needed to elucidate the role of the gut microbiota on the ADHD across the lifespan and its contribution to the persistence of the disorder from childhood to adulthood.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention

  • Soldevila-Domenech, Natalia
  • Fagundo, Ana Beatriz
  • Cuenca Royo, Aida
  • Forcano Gamazo, Laura
  • Gomis-Gonzalez, Maria
  • Boronat, Anna
  • Pastor, Antoni
  • Castañer, Olga
  • Zomeño, M. Dolores
  • Goday, Alberto
  • Dierssen, Mara
  • Baghizadeh Hosseini, Khashayar
  • Ros Rahola, Emilio
  • Corella Piquer, Dolores
  • Martínez-González, Miguel Ángel
  • Salas Salvadó, Jordi
  • Fernández-Aranda, Fernando
  • Fitó Colomer, Montserrat
  • de la Torre, Rafael
Background The Mediterranean diet (MedDiet) has demonstrated efficacy in preventing age-related cognitive decline and modulating plasma concentrations of endocannabinoids (eCBs) and N-acylethanolamines (NAEs, or eCB-like compounds), which are lipid mediators involved in multiple neurological disorders and metabolic processes. Hypothesizing that eCBs and NAEs will be biomarkers of a MedDiet intervention and will be related to the cognitive response, we investigated this relationship according to sex and apolipoprotein E (APOE) genotype, which may affect eCBs and cognitive performance. Methods This was a prospective cohort study of 102 participants (53.9% women, 18.8% APOE-ɛ4 carriers, aged 65.6 ± 4.5 years) from the PREDIMED-Plus-Cognition substudy, who were recruited at the Hospital del Mar Research Institute (Barcelona). All of them presented metabolic syndrome plus overweight/obesity (inclusion criteria of the PREDIMED-Plus) and normal cognitive performance at baseline (inclusion criteria of this substudy). A comprehensive battery of neuropsychological tests was administered at baseline and after 1 and 3 years. Plasma concentrations of eCBs and NAEs, including 2-arachidonoylglycerol (2-AG), anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and N-docosahexaenoylethanolamine (DHEA), were also monitored. Baseline cognition, cognitive changes, and the association between eCBs/NAEs and cognition were evaluated according to gender (crude models), sex (adjusted models), and APOE genotype. Results At baseline, men had better executive function and global cognition than women (the effect size of gender differences was − 0.49, p = 0.015; and − 0.42, p = 0.036); however, these differences became nonsignificant in models of sex differences. After 3 years of MedDiet intervention, participants exhibited modest improvements in memory and global cognition. However, greater memory changes were observed in men than in women (Cohen’s d of 0.40 vs. 0.25; p = 0.017). In men and APOE-ε4 carriers, 2-AG concentrations were inversely associated with baseline cognition and cognitive changes, while in women, cognitive changes were positively linked to changes in DHEA and the DHEA/AEA ratio. In men, changes in the OEA/AEA and OEA/PEA ratios were positively associated with cognitive changes. Conclusions The MedDiet improved participants’ cognitive performance but the effect size was small and negatively influenced by female sex. Changes in 2-AG, DHEA, the OEA/AEA, the OEA/PEA and the DHEA/AEA ratios were associated with cognitive changes in a sex- and APOE-dependent fashion. These results support the modulation of the endocannabinoid system as a potential therapeutic approach to prevent cognitive decline in at-risk populations., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide

  • Camara Sanchez, Patricia
  • Garcia Aranda, Natalia
  • Gener, Petra
  • Seras Franzoso, Joaquin
  • Giani Alonso, Micaela
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
Cancer stem cells; Combination therapy; Niclosamide, Células madre cancerosas; Terapia combinada; Niclosamida, Cèl·lules mare cancerígenes; Teràpia combinada; Niclosamida, Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. Here, we aimed to identify potential drugs targeting CSCs to be further employed in combination with standard chemotherapy in TNBC treatment. The anti-CSC efficacy of up to 17 small drugs was tested in TNBC cell lines using cell viability assays on differentiated cancer cells and CSCs. Then, the effect of 2 selected drugs (8-quinolinol -8Q- and niclosamide -NCS-) in the cancer stemness features were evaluated using mammosphere growth, cell invasion, migration and anchorage-independent growth assays. Changes in the expression of stemness genes after 8Q or NCS treatment were also evaluated. Moreover, the potential synergism of 8Q and NCS with PTX on CSC proliferation and stemness-related signaling pathways was evaluated using TNBC cell lines, CSC-reporter sublines, and CSC-enriched mammospheres. Finally, the efficacy of NCS in combination with PTX was analyzed in vivo using an orthotopic mouse model of MDA-MB-231 cells. Among all tested drug candidates, 8Q and NCS showed remarkable specific anti-CSC activity in terms of CSC viability, migration, invasion and anchorage independent growth reduction in vitro. Moreover, specific 8Q/PTX and NCS/PTX ratios at which both drugs displayed a synergistic effect in different TNBC cell lines were identified. The sole use of PTX increased the relative presence of CSCs in TNBC cells, whereas the combination of 8Q and NCS counteracted this pro-CSC activity of PTX while significantly reducing cell viability. In vivo, the combination of NCS with PTX reduced tumor growth and limited the dissemination of the disease by reducing circulating tumor cells and the incidence of lung metastasis. The combination of 8Q and NCS with PTX at established ratios inhibits both the proliferation of differentiated cancer cells and the viability of CSCs, paving the way for more efficacious TNBC treatments., This work was supported by the Instituto de Salud Carlos III (ISCiii), through Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), an initiative that also counts with the assistance from the European Regional Development Fund (ERDF), specifically in the PENTRI-2 Project and by the “Fundació Marató TV3” (337/C/2013) to I.A., M.R. and E.V. Our laboratories were also supported by the Fondo de Investigaciones Sanitarias (FIS, grants PI20/1474 to S.S.J. and PI18/00871 and PI21/00936), co-financed by the ERDF and the 2017-SGR-638 of the Catalan Government to S.S.J. and EvoNano Project (GA800983), funded by European Union’s Horizon 2020 FET Open Programme. N.G.-A. was supported by grants from Pla Estratègic de Recerca i Innovació en Salut (PERIS) of Catalonia (SLT006/17/00270 270).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dissecting the polygenic contribution of attention-deficit/hyperactivity disorder and autism spectrum disorder on school performance by their relationship with educational attainment

  • Bosch, Rosa
  • Carabí-Gassol, Pau
  • MACÍAS CHIMBORAZO, VALERIA
  • Español Martin, Gemma
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Attention-deficit/hyperactivity disorder; Autism spectrum disorder; School performance, Trastorn per dèficit d'atenció i hiperactivitat; Trastorn de l'espectre autista; Rendiment escolar, Trastorno por déficit de atención e hiperactividad; Trastorno del espectro autista; Rendimiento escolar, Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are strongly associated with educational attainment (EA), but little is known about their genetic relationship with school performance and whether these links are explained, in part, by the genetic liability of EA. Here, we aim to dissect the polygenic contribution of ADHD and ASD to school performance, early manifestation of psychopathology and other psychiatric disorders and related traits by their relationship with EA. To do so, we tested the association of polygenic scores for EA, ADHD and ASD with school performance, assessed whether the contribution of the genetic liability of ADHD and ASD to school performance is influenced by the genetic liability of EA, and evaluated the role of EA in the genetic overlap between ADHD and ASD with early manifestation of psychopathology and other psychiatric disorders and related traits in a sample of 4,278 school-age children. The genetic liability for ADHD and ASD dissected by their relationship with EA show differences in their association with school performance and early manifestation of psychopathology, partly mediated by ADHD and ASD symptoms. Genetic variation with concordant effects in ASD and EA contributes to better school performance, while the genetic variation with discordant effects in ADHD or ASD and EA is associated with poor school performance and higher rates of emotional and behavioral problems. Our results strongly support the usage of the genetic load for EA to dissect the genetic and phenotypic heterogeneity of ADHD and ASD, which could help to fill the gap of knowledge of mechanisms underlying educational outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404, PI23/00026 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Network Center for Biomedical Research (CIBER) to J.C.D.; the European Regional Development Fund (ERDF); the ECNP Network ‘ADHD across the Lifespan’; “la Marató de TV3” (202228-30 and 202228-31), “Fundació ‘la Caixa’, Diputació de Barcelona, Pla Estratègic de Recerca i Innovació en Salut” (PERISSLT006/17/285); “Fundació Privada d’Investigació Sant Pau” (FISP); and Ministry of Health of Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

  • Clougher, Derek
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana Maria
  • Serra-Navarro, Maria
  • Penadés , Rafael
  • Forte, Maria Florencia
  • Amoretti, Silvia
  • Ramos-Quiroga, Josep Antoni
Emotional intelligence; Emotional processing; Neurocognition, Inteligencia emocional; Procesamiento emocional; Neurocognición, Intel·ligència emocional; Processament emocional; Neurocognició, Emotional intelligence (EI) and neurocognition (NC) impairments are common in first-episode psychosis (FEP), yet their evolution over time remains unclear. This study identified patient profiles in EI and NC performance in FEP. 98 adult FEP patients and 128 healthy controls (HCs) were tested on clinical, functional, EI, and NC variables at baseline and two-year follow-up (FUP). A repeated-measures ANOVA compared the effects of group (patients and HCs) and time on EI. Significant EI improvements were observed in both groups. Four groups were created based on NC and EI performance at baseline and FUP in patients: impairment in NC and EI, impairment in NC only, impairment in EI only, and no impairment. At FUP, patients impaired in NC and EI showed less cognitive reserve (CR), greater negative and positive symptoms, and poorer functional outcomes. At FUP, three group trajectories were identified: (I) maintain dual impairment (II) maintain no impairment or improve, (III) maintain sole impairment or worsen. The maintain dual impairment group had the lowest levels of CR. EI and NC impairments progress differently in FEP. Greater CR may protect against comorbid EI/NC impairment. Identifying these patient characteristics could contribute to the development of personalised interventions., This study is part of a coordinated-multicentre Project, funded by the Ministerio de Economía y Competitividad (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, by the CERCA Programme / Generalitat de Catalunya AND Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2021 SGR 01120). Departament de Salut de la Generalitat de Catalunya, en la convocatòria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. This work was supported by La Marató-TV3 Foundation grants 202234-30 (to E. Vieta), 202234-32 (to S. Amoretti). S. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future”. MFF received the support of “Contratos predoctorales de formación en investigación en salud" (PFIS22) (FI22/00185) from the Instituto de Salud Carlos III (ISCIII) with European funds from the Recovery, Transformation and Resilience Plan, by virtue of the Resolution of the Directorate of the Carlos III Health Institute, O.A., M.P. of December 14, 2022, granting Predoctoral Research Training Contracts in Health (PFIS Contracts). Funded by the European Union – tGenerationEU. E. Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI18/00805; PI21/00787) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2021 SGR 1358) and the project SLT006/17/00357, from PERIS 2016-2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. A. González-Pinto thanks the support of the Spanish Ministry of Science, Innovation and Universities PI21/00713, PI18/01055 integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Basque Government 2022111054. C. Torrent thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI20/00344) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The negative impact of neurodevelopmental disorders and multiple co-occurring conditions on academic performance of school-age children and adolescents

  • Autet, Aurea
  • Pagespetit, Èlia
  • Andreu, Maria
  • Pagerols, Mireia
  • Prat, Raquel
  • Español Martin, Gemma
Academic performance; Co-occurring conditions; Neurodevelopmental disorders, Rendiment acadèmic; Condicions concurrents; Trastorns del neurodesenvolupament, Rendimiento académico; Condiciones concurrentes; Trastornos del neurodesarrollo, Students with neurodevelopmental disorders (ND) are at risk for academic impairment. However, the pervasive co-occurrence among these conditions has rarely been considered when evaluating this association. This study examined whether intellectual disabilities (ID), communication disorders, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), specific learning disorder (SLD), and motor disorders were related to academic outcomes. Parents and teachers completed standardized screening instruments for mental health problems and learning difficulties. Children who screened positive were interviewed for diagnostic confirmation according to the Diagnostic and Statistical Manual of Mental Disorders, while students who screened negative served as controls. Academic performance across multiple subjects was obtained from school records. The final sample comprised 9018 participants aged 5-17. Mixed-effects ordinal logistic regression models determined the independent and combined effects of ND on academic performance, adjusting for background and coexisting conditions. When examined separately, each diagnostic category was significantly associated with lower marks in all educational outcomes, even after adjusting for sociodemographic and school-related factors. However, when the influence of neurodevelopmental co-occurrence was controlled for, ID emerged as the strongest predictor of poor academic performance, followed by ADHD, SLD, and communication disorders. ASD and motor disorders were only associated with lower marks in arts and physical education. Furthermore, youth with coexisting conditions were at higher risk for academic impairment across all subjects. These findings highlight the need for early diagnosis and targeted interventions to address the specific educational needs of students with ND. Likewise, co-occurring diagnoses should be actively sought to avoid disadvantaging children with multiple disorders., This work was funded by Fundació “la Caixa” (LCR/PR/PR20/51150021), Diputació de Barcelona (PR(AG)72-2012 (2016/011627)), Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00285), Fundació La Marató de TV3 (202228-30-31), Fondo de Investigaciones Sanitarias (PI23/00026, PI23/00040), Agència de Gestió d’Ajuts Universitaris i de Recerca (DI-2024-00034), Fundació d’Investigació Salut i Progrés (FISP), and the Department of Health (Generalitat de Catalunya).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Relation between length of exposure to epidural analgesia during labour and birth mode

  • Garcia-Lausin, Laura
  • Perez-Botella, Mercedes
  • Duran, Xavier
  • Mamblona-Vicente, Maria Felisa
  • Gutierrez-Martin, Maria Jesus
  • Gómez de Enterria-Cuesta, Eugenia
  • Escuriet, Ramon
Objective: To appraise the relationship between the length of exposure to epidural analgesia and the risk of non-spontaneous birth, and to identify additional risk factors. This study is framed within the MidconBirth project. Study design: A multicentre prospective study was conducted between July 2016 and November 2017 in three maternity hospitals in different Spanish regions. The independent variable of the study was the length of exposure to epidural analgesia, and the dependent variable was the type of birth in women with uncomplicated pregnancies. The data was analyzed separately by parity. A multivariate logistic regression was performed. The odds ratios (OR), using 95% confidence intervals (CI) were constructed. Main outcome measures: During the study period, 807 eligible women gave birth. Non-spontaneous births occurred in 29.37% of the sample, and 75.59% received oxytocin for augmentation of labour. The mean exposure length to epidural analgesia when non-spontaneous birth happened was 8.05 for primiparous and 6.32 for multiparous women (5.98 and 3.37 in spontaneous birth, respectively). A logistic regression showed the length of exposure to epidural during labour was the major predictor for non-spontaneous births in primiparous and multiparous women followed by use of oxytocin (multiparous group). Conclusions: The length of exposure to epidural analgesia during labour is associated with non-spontaneous births in our study. It highlights the need for practice change through the development of clinical guidelines, training programs for professionals and the continuity of midwifery care in order to support women to cope with labour pain using less invasive forms of analgesia. Women also need to be provided with evidence-based information., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

  • Walters, Raymond K.
  • Rajagopal, Veera M.
  • Waldman, Irwin D.
  • Grove, Jakob
  • Als, Thomas D.
  • Ribases Haro, Marta
  • Demontis, Ditte
TDAH; Genoma; Estudios de asociación amplia, ADHD; Genome; Wide association studies, TDAH; Genoma; Estudis d'associació ample, Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood psychiatric disorder often comorbid with disruptive behavior disorders (DBDs). Here, we report a GWAS meta-analysis of ADHD comorbid with DBDs (ADHD + DBDs) including 3802 cases and 31,305 controls. We identify three genome-wide significant loci on chromosomes 1, 7, and 11. A meta-analysis including a Chinese cohort supports that the locus on chromosome 11 is a strong risk locus for ADHD + DBDs across European and Chinese ancestries (rs7118422, P = 3.15×10−10, OR = 1.17). We find a higher SNP heritability for ADHD + DBDs (h2SNP = 0.34) when compared to ADHD without DBDs (h2SNP = 0.20), high genetic correlations between ADHD + DBDs and aggressive (rg = 0.81) and anti-social behaviors (rg = 0.82), and an increased burden (polygenic score) of variants associated with ADHD and aggression in ADHD + DBDs compared to ADHD without DBDs. Our results suggest an increased load of common risk variants in ADHD + DBDs compared to ADHD without DBDs, which in part can be explained by variants associated with aggressive behavior.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Functioning assessment short test (FAST): validity and reliability in adults with Autism Spectrum Disorder

  • Gisbert Gustemps, Laura
  • Lugo Marin, Jorge
  • Español Martín, Gemma
  • Bonnín, C. Mar
  • Vieta, Eduard
  • Setien Ramos, Imanol
  • Ramos-Quiroga, Josep Antoni
Quocient de l'espectre de l'autisme; Anàlisi factorial; Fiabilitat, Cociente del espectro autista; Análisis factorial; Fiabilidad, Autism Spectrum quotient; Factor analysis; Reliability, Background The assessment of functional impairment is crucial both for the diagnosis and the therapeutic approach to autism spectrum disorder (ASD). The purpose of the present study was to evaluate whether the FAST is a reliable and valid tool to assess functional impairment in adults with Level 1 ASD and to study the differences in psychosocial functioning between younger and older adults with ASD. Methods A case–control study was carried out in a sample of 150 participants, 71 adults with Level 1 ASD, and 79 adults without psychiatric history records. Results Results showed good psychometric properties in terms of validity and reliability. Cronbach’s alpha for the total scale was .91 and the area under the curve was .98. The study also showed that adults with ASD present different profiles of functional impairment depending on their age: while younger patients present greater impairment in autonomy, older patients show more difficulties in interpersonal relationships. Conclusions Our results support the use of the FAST in the evaluation of adaptive functioning in adults with Level 1 ASD., The author ISR is currently funded by the Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT006/17/00287) and Instituto de Salud Carlos III (PI18/01788). The funders played no part in study design, collection, management, and interpretation of the data; writing the report; or the decision to submit the report for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-term association between water intake and kidney function in a population at high cardiovascular risk

  • Paz Graniel, Indira
  • Valle Hita, Cristina
  • Babio, Nancy
  • Serra Majem, Lluís
  • Vioque, Jesús
  • Zomeño, M. Dolores
  • Corella Piquer, Dolores
  • Pintó Sala, Xavier
  • Cano-Ibáñez, Naomi
  • Tur, Josep A.
  • Cuadrado-Soto, Esther
  • Martínez, José Alfredo
  • Díaz López, Andrés
  • Torres-Collado, Laura
  • Goday, Alberto
  • Fernández-Carrión, Rebeca
  • Nissenshon, Mariela
  • Riera-Mestre, Antoni
  • Garrido-Garrido, Eva
  • Bouzas, Cristina
  • Abete, Itziar
  • Daimiel, Lidia
  • Cornejo-Pareja, Isabel María
  • Vázquez Ruiz, Zenaida
  • Khoury, Nadine
  • Pérez-Vega, Karla Alejandra
  • Salas Salvadó, Jordi
Objectives The evidence on water intake in the prevention of kidney function decline is scarce at population level in well-being individuals at high cardiovascular risk. Therefore, we aimed to longitudinally evaluate the associations between total water intake and subtypes and kidney function, through estimated-Glomerular Filtration Rate (eGFR). Methods Three-year prospective analysis conducted in 1986 older adults (aged 55–75 year) with overweight/obesity and metabolic syndrome from the PREDIMED-Plus study. Water intake was assessed using validated beverage and food frequency questionnaires. Serum creatinine-based eGFR (SCr-based eGFR; ml/min/1.73 m2) was estimated using the CKD-EPI equation at baseline, one-year and 3-years of follow-up. Mixed-effects linear regression models were fitted to evaluate the associations between baseline total water intake and subtypes, and SCr-based eGFR over 3-years of follow-up. Results Participants in the highest baseline tertile of total water intake, plain water and water from all fluids showed a lower decrease in SCr-based eGFR after 3-years of follow-up, compared to those in the lowest tertile. Participants with the highest tap water consumption showed a lower SCr-based eGFR decline after 1-year and 3-years of follow-up, in comparerd to participants in the lowest intake category (T3 vs. T1: β: 1.4 ml/min/1.73 m2; 95%CI: 0.5–2.3, β: 1.0; 95%CI: 0.1–2.0, respectively). Conclusions Plain water rather than other water sources, and especially tap water, was associated with lower kidney function decline assessed through eGFR over 3-years of follow-up, in older individuals at high cardiovascular risk., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

New candidate blood biomarkers potentially associated with white matter hyperintensities progression

  • Jimenez Balado, Joan
  • Pizarro Gonzálvez, Jesús
  • Riba Llena, Yolanda
  • Penalba Morenilla, Anna
  • Faura Llorens, Julia
  • Pala Vila, Elena
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
  • Delgado Martínez, Maria Pilar
Barrera hematoencefàlica; Interaccions neurovasculars; Neurociència, Barrera hematoencefálica; Interacciones neurovasculares; Neurociencia, Blood-brain barrier; Neuro-vascular interactions; Neuroscience, We aimed to discover blood biomarkers associated with longitudinal changes in white matter hyperintensities (WMH). This study was divided into a discovery phase and a replication phase. Subjects in both studies were patients with hypertension, aged 50-70, who underwent two magnetic resonance imaging (MRI) sessions and blood extractions over a 4-year follow-up period. In the discovery phase, we screened 1305 proteins in 12 subjects with WMH progression and in 12 matched control subjects. We found that 41 proteins were differentially expressed: 13 were upregulated and 28 were downregulated. We subsequently selected three biomarkers for replication in baseline and follow-up samples in 80 subjects with WMH progression and in 80 control subjects. The selected protein candidates for the replication were MMP9 (matrix metalloproteinase-9), which was higher in cases, MET (hepatocyte growth factor receptor) and ASAH2 (neutral ceramidase), which were both lower in cases of WMH progression. Baseline biomarker concentrations did not predict WMH progression. In contrast, patients with WMH progression presented a steeper decline in MET over time. Furthermore, cases showed higher MMP9 and lower ASAH2 levels than controls at the follow-up. These results indicate that MMP9, MET, and ASAH2 are potentially associated with the progression of WMH, and could therefore be interesting candidates to validate in future studies., Funds were obtained from the Instituto de Salud Carlos III (Grant Numbers: PI14/01535, PI17/02222, ICI14/307, PI19/00217, CP15/00010, and JR15/00032), incorporation of scientists and technicians to research groups (PERIS, SLT006/17/00266) and the AGAUR (FI_DGR 2017, Grant Number 2017_FI_B 00064), with the support of the Secretary of Universities and Research (Department of Economy and Knowledge, Generalitat de Catalunya), and was cofinanced by the European Regional Development Fund. The neurovascular research laboratory receives funds from the Spanish research stroke network (RD/16/0019/0021).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy

  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Simón Talero, Manuel J.
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Moga, Esther|||0000-0003-4264-6910
  • Juárez Rubio, Cándido|||0000-0003-2235-9893
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A multicenter phase II rater-blinded randomized controlled trial to compare the effectiveness of eye movement desensitization reprocessing therapy vs. Treatment as usual in patients with substance use disorder and history of psychological trauma, A study design and protocol

  • Valiente-Gómez, Alicia|||0000-0003-0220-2397
  • Moreno Alcázar, Ana|||0000-0002-3392-5590
  • Radua, Joaquim|||0000-0003-1240-5438
  • Hogg, Bridget|||0000-0002-2405-0593
  • Blanco Presas, Laura|||0000-0001-6272-4416
  • Lupo, Walter
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Robles-Martínez, María|||0000-0003-0324-8354
  • Torrens, Marta|||0000-0001-6222-4761
  • Amann, Benedikt L.|||0000-0002-4407-1519
Background: Psychological trauma has a strong negative impact on the onset, course and prognosis of substance use disorders (SUD). Few trauma-oriented treatment approaches have been trialed, but preliminary evidence exists of the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy in improving clinical symptoms in SUD patients. Objective: To assess if EMDR therapy leads to: (1) reduced substance consumption; (2) an improvement in psychopathological and in trauma-related symptoms; and (3) an improvement in overall functioning. Our hypothesis is that the EMDR group will improve in all variables when compared to the treatment as usual (TAU) group at 6 and 12-months visits. Method: In this multicenter phase II rater-blinded randomized controlled trial, 142 SUD patients with a history of psychological trauma will be randomly assigned to EMDR (n = 71) or to TAU (n = 71). Patients in the EMDR group will receive 20 psychotherapeutic sessions of 60 min over 6 months. Substance use will be measured using the Timeline Followback Questionnaire, the Dependence Severity Scale and the Visual Analog Scale. Traumatic events will be measured by The Holmes-Rahe Life Stress Inventory, the Childhood Trauma Questionnaire Scale, the Global Assessment of Posttraumatic Stress Questionnaire, the Impact of Event Scale-Revised and the Dissociative Experiences Scale. Clinical symptomatology will be evaluated using the Hamilton Depression Rating Scale, the Young Mania Rating Scale and the Brief Psychiatric Rating Scale. Functionality will be assessed with the Functioning Assessment Short Test. All variables will be measured at baseline, post-treatment and 12 months as follow-up. Primary outcome: to test the efficacy of EMDR therapy in reducing the severity of substance use. The secondary outcomes: to test the efficacy in reducing trauma-related psychological symptoms and psychopathological symptoms and in improving overall functioning in patients with comorbid SUD and a history of psychological trauma. Conclusion: This study will provide evidence of whether EMDR therapy is effective in reducing addiction-related, trauma and clinical symptoms and in improving functionality in patients with SUD and a history of trauma.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Therapeutic Use of LSD in Psychiatry, A Systematic Review of Randomized-Controlled Clinical Trials

  • Fuentes, Juan José
  • Fonseca, Francina|||0000-0002-0779-6545
  • Elices, M.|||0000-0002-7034-4242
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Muñoz, Laia|||0000-0003-0578-3094
  • Camacho, Valle|||0000-0003-0748-0847
  • Lopez Mora, Diego Alfonso|||0000-0002-3533-7362
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Le Bastard, Nathalie
  • Huyck, Else
  • Nadal, Alicia
  • Olmedo, Verónica
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Moderators and mediators of antipsychotic response in delusional disorder, Further steps are needed

  • González-Rodríguez, Alexandre|||0000-0003-1855-8566
  • Guàrdia Delgado, Armand|||0000-0002-3908-0875
  • Palao, Diego|||0000-0002-3323-6568
  • Labad, Javier|||0000-0003-2214-1886
  • Seeman, Mary|||0000-0001-6797-3382
Delusional disorder (DD) has been traditionally considered a relatively rare and treatment-resistant psychotic disorder. In the last decade, increasing attention has focused on therapeutic outcomes of individuals affected by this disorder. The aim of this paper is to provide a synthesis of the literature addressing two very important questions arising from DD research: (1) For which patients with DD do antipsychotic medications work best (the moderators of response); and (2) What variables best explain the relationship between such treatments and their effectiveness (the mediators of response). We searched PubMed and Google Scholar databases for English, German, French and Spanish language papers published since 2000. We also included a few classic earlier papers addressing this topic. Variables potentially moderating antipsychotic response in DD are gender, reproductive status, age, duration of illness, the presence of comorbidity (especially psychiatric comorbidity) and its treatment, brain structure, and genetics of neurochemical receptors and drug metabolizing enzymes. Antipsychotic and hormonal blood levels during treatment, as well as functional brain changes, are potential mediating variables. Some, but not all, patients with DD benefit from antipsychotic treatment. Understanding the circumstances under which treatment works best can serve to guide optimal management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy

  • De Simoni, Desiree
  • Ricken, Gerda
  • Winklehner, Michael
  • Koneczny, Inga
  • Karenfort, Michael
  • Hustedt, Ulf
  • Seidel, Ulrich
  • Abdel-Mannan, Omar|||0000-0002-0796-9645
  • Munot, Pinki
  • Rinaldi, Simon|||0000-0003-2039-3457
  • Steen, Claudia
  • Freilinger, Michael
  • Breu, Markus|||0000-0003-3825-5749
  • Seidl, Rainer
  • Reindl, Markus|||0000-0003-2817-1402
  • Wanschitz, Julia|||0000-0002-0207-9977
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Bernert, Günther
  • Wandinger, Klaus-Peter
  • Junker, Ralf
  • Querol, Luis|||0000-0002-4289-8264
  • Leypoldt, Frank
  • Rostásy, Kevin
  • Höftberger, Romana|||0000-0002-5769-1100
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Pané, Adriana|||0000-0002-7810-1827
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • Casajoana, Anna
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Vidal, Josep|||0000-0002-4564-4518
  • Ortega, Emilio|||0000-0002-2217-8905
  • Osorio, Ricardo|||0000-0002-2735-9609
  • Convit, Antonio
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. We selected controls from ADNI2 with CSF AD biomarkers and/or fluorodeoxyglucose positron emission tomography (FDG-PET) and 3T-MRI. We measured cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1-42, p-tau, and t-tau levels. We performed regression analyses between these biomarkers and body mass index (BMI). We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m 2). Higher BMI was related to less cortical thickness and higher metabolism in brain areas typically not involved in AD (family-wise error [FWE] <0.05), but not to AD CSF biomarkers. It is notable that the impact of obesity on brain metabolism and structure was also found in amyloid negative individuals. In the cognitively unimpaired elderly, obesity has differential effects on brain metabolism and structure independent of an underlying AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Shared genetic background between children and adults with attention deficit/hyperactivity disorder

  • Rovira, Paula|||0000-0003-2177-8412
  • Demontis, Ditte|||0000-0001-9124-2766
  • Sánchez-Mora, Cristina|||0000-0003-4211-1107
  • Zayats, Tetyana
  • Klein, Marieke|||0000-0001-8784-5679
  • Mota, Nina Roth
  • Weber, Heike|||0000-0002-9421-1292
  • García-Martinez, Iris|||0000-0001-6656-3322
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Arribas, Lorena|||0000-0002-9683-9999
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Bosch, Rosa|||0000-0002-7596-183X
  • Martin, Gemma Español
  • Almos, Peter
  • Doyle, Alysa E.
  • Grevet, Eugenio Horacio
  • Grimm, Oliver|||0000-0002-0767-0301
  • Halmøy, Anne
  • Hoogman, Martine|||0000-0002-1261-7628
  • Hutz, Mara
  • Jacob, Christian P.
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Knappskog, Per M.
  • Lundervold, Astri J.|||0000-0002-6819-6164
  • Rivero, Olga|||0000-0002-2664-4053
  • Rovaris, Diego Luiz|||0000-0002-8910-4927
  • Salatino-Oliveira, Angelica
  • da Silva, Bruna Santos
  • Svirin, Evgeniy|||0000-0003-3501-574X
  • Sprooten, Emma
  • Strekalova, Tatyana
  • Arias-Vásquez, Alejandro|||0000-0002-4786-0169
  • Sonuga-Barke, Edmund J. S.
  • Asherson, Philip|||0000-0003-2667-2254
  • Bau, Claiton Henrique Dotto
  • Buitelaar, Jan|||0000-0001-8288-7757
  • Cormand, Bru|||0000-0001-5318-4382
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Haavik, Jan|||0000-0001-7865-2808
  • Johansson, Stefan E.|||0000-0002-2298-7008
  • Kuntsi, Jonna|||0000-0002-0113-8162
  • Larsson, Henrik
  • Lesch, Klaus-Peter|||0000-0001-8348-153X
  • Reif, Andreas|||0000-0002-0992-634X
  • Rohde, Luis Augusto
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Franke, Barbara|||0000-0003-4375-6572
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Soler Artigas, María|||0000-0002-3213-1107
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by age-inappropriate symptoms of inattention, impulsivity, and hyperactivity that persist into adulthood in the majority of the diagnosed children. Despite several risk factors during childhood predicting the persistence of ADHD symptoms into adulthood, the genetic architecture underlying the trajectory of ADHD over time is still unclear. We set out to study the contribution of common genetic variants to the risk for ADHD across the lifespan by conducting meta-analyses of genome-wide association studies on persistent ADHD in adults and ADHD in childhood separately and jointly, and by comparing the genetic background between them in a total sample of 17,149 cases and 32,411 controls. Our results show nine new independent loci and support a shared contribution of common genetic variants to ADHD in children and adults. No subgroup heterogeneity was observed among children, while this group consists of future remitting and persistent individuals. We report similar patterns of genetic correlation of ADHD with other ADHD-related datasets and different traits and disorders among adults, children, and when combining both groups. These findings confirm that persistent ADHD in adults is a neurodevelopmental disorder and extend the existing hypothesis of a shared genetic architecture underlying ADHD and different traits to a lifespan perspective.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

  • Radua, Joaquim|||0000-0003-1240-5438
  • Vieta, Eduard|||0000-0002-0548-0053
  • Shinohara, Russell
  • Kochunov, Peter
  • Quidé, Yann|||0000-0002-8569-7139
  • Green, Melissa J.
  • Weickert, Cynthia S.
  • Weickert, Thomas
  • Bruggemann, Jason
  • Kircher, Tilo|||0000-0002-2514-2625
  • Nenadić, Igor|||0000-0002-0749-7473
  • Cairns, Murray J.
  • Seal, Marc
  • Schall, Ulrich
  • Henskens, Frans
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Mowry, Bryan
  • Pantelis, Christos|||0000-0002-9565-0238
  • Lenroot, Rhoshel
  • Cropley, Vanessa
  • Loughland, Carmel
  • Scott, Rodney
  • Wolf, Daniel H.
  • Satterthwaite, Theodore D.|||0000-0001-7072-9399
  • Tan, Yunlong
  • Sim, Kang|||0000-0003-3209-9626
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Solanes, Aleix|||0000-0002-2491-200X
  • Albajes-Eizagirre, Anton
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Sarro, Salvador
  • Giorgio, Annabella Di
  • Bertolino, Alessandro
  • Stäblein, Michael
  • Oertel, Viola
  • Knöchel, Christian
  • Borgwardt, Stefan
  • du Plessis, Stefan
  • Yun, Je-Yeon|||0000-0002-5531-2410
  • Kwon, Jun Soo|||0000-0002-1060-1462
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Hahn, Tim|||0000-0002-8929-4134
  • Grotegerd, Dominik
  • Alloz, Clara
  • Arango, Celso|||0000-0003-3382-4754
  • Janssen, Joost|||0000-0001-7613-2067
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Jiang, Wenhao
  • Calhoun, Vince
  • Ehrlich, Stefan|||0000-0003-2132-4445
  • Yang, Kun
  • Cascella, Nicola G.
  • Takayanagi, Yoichiro
  • Sawa, Akira
  • Tomyshev, Alexander
  • Lebedeva, Irina
  • Kaleda, Vasily
  • Kirschner, Matthias
  • Hoschl, Cyril
  • Tomecek, David
  • Skoch, Antonin
  • van Amelsvoort, Therese
  • Bakker, Geor
  • James, Anthony|||0000-0002-2742-8328
  • Preda, Adrian
  • Weideman, Andrea
  • Stein, Dan J.|||0000-0001-7218-7810
  • Howells, Fleur
  • Uhlmann, Anne|||0000-0002-1753-7811
  • Temmingh, Henk
  • López-Jaramillo, Carlos
  • Díaz-Zuluaga, Ana M..
  • Fortea, Lydia|||0000-0001-6778-2316
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
  • Jahanshad, Neda|||0000-0003-4401-8950
  • Thompson, Paul
  • Turner, Jessica A.
  • van Erp, Theo
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Traumatic events in dual disorders, prevalence and clinical characteristics

  • Blanco Presas, Laura|||0000-0001-6272-4416
  • Sió, Albert
  • Hogg, Bridget|||0000-0002-2405-0593
  • Esteve-Puig, R.|||0000-0003-0547-1752
  • Radua, Joaquim|||0000-0003-1240-5438
  • Solanes, Aleix|||0000-0002-2491-200X
  • Gardoki-Souto, Itxaso|||0000-0002-0775-1275
  • Sauras, Rosa
  • Farré Martínez, Adriana|||0000-0001-5399-9389
  • Castillo, Claudio
  • Valiente Gomez, Alicia|||0000-0003-0220-2397
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Torrens, Marta
  • Amann, Benedikt L.|||0000-0002-4407-1519
  • Moreno Alcázar, Ana|||0000-0002-3392-5590
Psychological trauma has been identified in substance use disorders (SUD) as a major etiological risk factor. However, detailed and systematic data about the prevalence and types of psychological trauma in dual disorders have been scarce to date. In this study, 150 inpatients were recruited and cross-sectionally screened on their substance use severity, psychological trauma symptoms, comorbidities, and clinical severity. One hundred patients fulfilled criteria for a dual disorder, while 50 patients were diagnosed with only SUD. Ninety-four percent of the whole sample suffered from at least one lifetime traumatic event. The prevalence rates of Posttraumatic Stress Disorder diagnosis for dual disorder and only SUD was around 20% in both groups; however, patients with dual disorder presented more adverse events, more childhood trauma, more dissociative symptoms, and a more severe clinical profile than patients with only SUD. Childhood maltreatment can also serve as a predictor for developing a dual disorder diagnosis and as a risk factor for developing a more complex and severe clinical profile. These data challenge our current clinical practice in the treatment of patients suffering from dual disorder or only SUD diagnosis and favor the incorporation of an additional trauma-focused therapy in this population. This may improve the prognosis and the course of the illness in these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Sleep Quality, Trait Anxiety and Hypothalamic-Pituitary-Adrenal Axis Measures in Cognitive Abilities of Healthy Individuals

  • Labad, Javier|||0000-0003-2214-1886
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
  • Crespo, José Manuel
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Palao, Diego|||0000-0002-3323-6568
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Armario Garcia, Antonio|||0000-0001-9524-3635
  • Cabezas, Ángel|||0000-0001-8114-0264
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Nadal i Alemany, Roser|||0000-0001-8972-2525
  • Martorell, Lourdes|||0000-0003-4999-2197
Sleep plays a crucial role in cognitive processes. Sleep and wake memory consolidation seem to be regulated by glucocorticoids, pointing out the potential role of the hypothalamic-pituitary-adrenal (HPA) axis in the relationship between sleep quality and cognitive abilities. Trait anxiety is another factor that is likely to moderate the relationship between sleep and cognition, because poorer sleep quality and subtle HPA axis abnormalities have been reported in people with high trait anxiety. The current study aimed to explore whether HPA axis activity or trait anxiety moderate the relationship between sleep quality and cognitive abilities in healthy individuals. We studied 203 healthy individuals. We measured verbal and visual memory, working memory, processing speed, attention and executive function. Sleep quality was assessed with the Pittsburgh Sleep Quality Index. Trait anxiety was assessed with the State-Trait Anxiety Inventory. HPA axis measures included the cortisol awakening response (CAR), diurnal cortisol slope and cortisol levels during the day. Multiple linear regression analyses explored the relationship between sleep quality and cognition and tested potential moderating effects by HPA axis measures and trait anxiety. Poor sleep quality was associated with poorer performance in memory, processing speed and executive function tasks. In people with poorer sleep quality, a blunted CAR was associated with poorer verbal and visual., memory and executive functions, and higher cortisol levels during the day were associated with poorer processing speed. Trait anxiety was a moderator of visual memory and executive functioning. These results suggest that subtle abnormalities in the HPA axis and higher trait anxiety contribute to the relationship between lower sleep quality and poorer cognitive functioning in healthy individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke|||0000-0002-6005-417X
  • Costa, Alberto C. S.
  • Dierssen, Mara|||0000-0003-0853-6865
  • Baksh, Asaad|||0000-0001-6596-2145
  • Bargagna, Stefania
  • Baumer, Nicole
  • Brandão, Ana Claudia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Chicoine, Brian|||0000-0002-1520-3893
  • Ghosh, Sujay
  • Lakhanpaul, Monica
  • Manso, Coral
  • Mayer, Miguel-Angel
  • Ortega, Maria del Carmen
  • de Asua, Diego Real
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Russell, Lauren Ashley
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Sherman, Stephanie L.
  • Strydom, Andre
Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method

  • Merlo-Mas, Josep
  • Tomsen Melero, Judit|||0000-0002-2837-8107
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • González Mira, Elisabet
  • Font, Albert|||0000-0003-3908-1111
  • Pedersen, Jannik N.
  • García Aranda, Natalia|||0000-0003-3230-9881
  • Cristóbal-Lecina, Edgar
  • Alcaina Hernando, Marta
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Lizarraga, Teresa
  • Resch, Susanne
  • Schimpel, Christa
  • Falk, Andreas
  • Pulido, Daniel|||0000-0002-2841-194X
  • Royo, Miriam|||0000-0001-5292-0819
  • Schwartz, Simon|||0000-0001-8297-7971
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Pedersen, Jan Skov|||0000-0002-7768-0206
  • Danino, Dganit
  • Soldevila, Andreu
  • Veciana i Miró, Jaume|||0000-0003-1023-9923
  • Sala, Santi
  • Ventosa, Nora|||0000-0002-8008-4974
  • Córdoba, Alba
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA). The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular, cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently, lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration of the missing enzyme to the patients. In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability. Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed fluid-based method that allows the reproducible and scalable production of nanovesicular systems with remarkable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes (nanoGLA) for the treatment of Fabry disease. Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation. This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo preclinical testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone

  • Estellés, Teresa
  • Zhu, Nuole|||0000-0002-0015-9455
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Subirana, Andrea
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Belbin, Olivia|||0000-0002-6109-6371
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10.1186/s13195-022-00967-z.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis

  • Salagre, Estela|||0000-0001-6352-5179
  • Grande, Iria|||0000-0002-0137-0666
  • Solé, Brisa|||0000-0003-1673-8248
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Cuesta, Manuel J.|||0000-0003-0250-5718
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Moreno, Carmen|||0000-0003-0541-4846
  • Pina-Camacho, Laura|||0000-0003-1960-6443
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Baeza, Inmaculada|||0000-0003-2611-5781
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Verdolini, Norma|||0000-0001-9488-2881
  • Carvalho, André F.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Bernardo, Miquel|||0000-0001-8748-6717
Being able to predict functional outcomes after First-Episode Psychosis (FEP) is a major goal in psychiatry. Thus, we aimed to identify trajectories of psychosocial functioning in a FEP cohort followed-up for 2 years in order to find premorbid/baseline predictors for each trajectory. Additionally, we explored diagnosis distribution within the different trajectories. A total of 261 adults with FEP were included. Latent class growth analysis identified four distinct trajectories: Mild impairment-Improving trajectory (Mi-I) (38.31% of the sample), Moderate impairment-Stable trajectory (Mo-S) (18.39%), Severe impairment-Improving trajectory (Se-I) (12.26%), and Severe impairment-Stable trajectory (Se-S) (31.03%). Participants in the Mi-I trajectory were more likely to have higher parental socioeconomic status, less severe baseline depressive and negative symptoms, and better premorbid adjustment than individuals in the Se-S trajectory. Participants in the Se-I trajectory were more likely to have better baseline verbal learning and memory and better premorbid adjustment than those in the Se-S trajectory. Lower baseline positive symptoms predicted a Mo-S trajectory vs. Se-S trajectory. Diagnoses of Bipolar disorder and Other psychoses were more prevalent among individuals falling into Mi-I trajectory. Our findings suggest four distinct trajectories of psychosocial functioning after FEP. We also identified social, clinical, and cognitive factors associated with more resilient trajectories, thus providing insights for early interventions targeting psychosocial functioning.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dealing with heterogeneity of cognitive dysfunction in acute depression, a clustering approach

  • Vicent Gil, Muriel|||0000-0001-7534-5095
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
  • Crivillés, Sara|||0000-0003-2787-4069
  • Aguilar, Eva|||0000-0003-1877-1471
  • Palao, Diego|||0000-0002-3323-6568
  • Cardoner, Narcís|||0000-0001-9633-0888
Heterogeneity in cognitive functioning among major depressive disorder (MDD) patients could have been the reason for the small-to-moderate differences reported so far when it is compared to other psychiatric conditions or to healthy controls. Additionally, most of these studies did not take into account clinical and sociodemographic characteristics that could have played a relevant role in cognitive variability. This study aims to identify empirical clusters based on cognitive, clinical and sociodemographic variables in a sample of acute MDD patients. In a sample of 174 patients with an acute depressive episode, a two-step clustering analysis was applied considering potentially relevant cognitive, clinical and sociodemographic variables as indicators for grouping. Treatment resistance was the most important factor for clustering, closely followed by cognitive performance. Three empirical subgroups were obtained: cluster 1 was characterized by a sample of non-resistant patients with preserved cognitive functioning (n = 68, 39%); cluster 2 was formed by treatment-resistant patients with selective cognitive deficits (n = 66, 38%) and cluster 3 consisted of resistant (n = 23, 58%) and non-resistant (n = 17, 42%) acute patients with significant deficits in all neurocognitive domains (n = 40, 23%). The findings provide evidence upon the existence of cognitive heterogeneity across patients in an acute depressive episode. Therefore, assessing cognition becomes an evident necessity for all patients diagnosed with MDD, and although treatment resistant is associated with greater cognitive dysfunction, non-resistant patients can also show significant cognitive deficits. By targeting not only mood but also cognition, patients are more likely to achieve full recovery and prevent new relapses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of biochemical and hematological parameters in adults with Down syndrome

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garzón, Diana
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fortea, Juan|||0000-0002-1340-638X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries.
Dipòsit Digital de Documents de la UAB
Publicación Otros (Other)

Excellent Response to Plasma Exchange in Three Patients With Enterovirus-71 Neurological Disease

  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Josa, Maria
  • Launes, Cristian|||0000-0002-0913-9303
  • Querol, Luis|||0000-0002-4289-8264
  • del Cuerpo Casas, Margarita|||0000-0001-7973-5496
  • Bosch, M. Alba
  • Jordán García, Iolanda|||0000-0002-2041-4425
  • Turon Viñas, Eulalia|||0000-0001-6171-0282
The clinical spectrum of Enterovirus-71-associated neurological disease includes acute flaccid paralysis, encephalomyelitis, or brainstem encephalitis with autonomic dysfunction. As no specific antiviral treatments are available, intravenous human immunoglobulin is used in early stages of the illness, decreasing serum proinflammatory cytokines, and improving clinical outcomes. Plasma exchange aims to eliminate pathogenic autoantibodies and proinflammatory cytokines, and is used in diverse immune-mediated neurologic conditions. However, its effect in Enterovirus-71 infections is unknown. We report three cases of severe Enterovirus-71 neurological disease treated with plasma exchange during an outbreak in Catalonia (Spain) in 2016. We observed a striking improvement in all three patients within 48 h of starting plasma exchange. Patients received four to six sessions every other day. Good outcomes were confirmed at the 1-year follow-up visit. Our observations suggest that plasma exchange is an effective complementary therapy for severe Enterovirus-71 neurological disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders

  • Ramírez, Sara
  • Haddad-Tóvolli, Roberta
  • Radosevic, Marija
  • Toledo, Miriam
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Ribas Ripoll, Vicent|||0000-0002-7266-6106
  • Milà-Guasch, Maria
  • Pozo, Macarena
  • Obri, Arnaud
  • Eyre Sánchez, Elena
  • Gómez-Valadés, Alicia G.
  • Chivite, Iñigo
  • Van Eeckhout, Tomas
  • Zalachoras, Ioannis
  • Altirriba, Jordi
  • Bauder, Corinna
  • Imbernón, Mónica
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Garcia-Ruiz, Carmen
  • Nogueiras, Rubén|||0000-0002-9976-9930
  • Soto, David
  • Gasull, Xavier|||0000-0002-6154-8323
  • Sandi, Carmen|||0000-0001-7713-8321
  • Brüning, Jens C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Fernández-Checa, José C.
  • Claret, Marc
Obesity and type 2 diabetes are associated with cognitive dysfunction. Because the hypothalamus is implicated in energy balance control and memory disorders, we hypothesized that specific neurons in this brain region are at the interface of metabolism and cognition. Acute obesogenic diet administration in mice impaired recognition memory due to defective production of the neurosteroid precursor pregnenolone in the hypothalamus. Genetic interference with pregnenolone synthesis by Star deletion in hypothalamic POMC, but not AgRP neurons, deteriorated recognition memory independently of metabolic disturbances. Our data suggest that pregnenolone's effects on cognitive function were mediated via an autocrine mechanism on POMC neurons, influencing hippocampal long-term potentiation. The relevance of central pregnenolone on cognition was also confirmed in metabolically unhealthy patients with obesity. Our data reveal an unsuspected role for POMC neuron-derived neurosteroids in cognition. These results provide the basis for a framework to investigate new facets of POMC neuron biology with implications for cognitive disorders. Ramírez et al. show that reduced hypothalamic pregnenolone levels, in the context of metabolic diseases, are associated with cognitive deterioration. POMC neuron-derived pregnenolone is a key mediator of cognition, but not metabolism, acting via hippocampal mechanisms. These results identify an unsuspected role for POMC neuron-derived pregnenolone in memory performance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma

  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Álamo, Patricia|||0000-0003-0510-5701
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Quer, Miquel|||0000-0003-2563-6729
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Therapy resistance, which leads to the development of loco-regional relapses and distant metastases after treatment, constitutes one of the major problems that head and neck squamous cell carcinoma (HNSCC) patients currently face. Thus, novel therapeutic strategies are urgently needed. Targeted drug delivery to the chemokine receptor 4 (CXCR4) represents a promising approach for HNSCC management. In this context, we have developed the self-assembling protein nanotoxins T22-PE24-H6 and T22-DITOX-H6, which incorporate the de-immunized catalytic domain of Pseudomonas aeruginosa (PE24) exotoxin A and the diphtheria exotoxin (DITOX) domain, respectively. Both nanotoxins contain the T22 peptide ligand to specifically target CXCR4-overexpressing HNSCC cells. In this study, we evaluate the potential use of T22-PE24-H6 and T22-DITOX-H6 nanotoxins for the treatment of HNSCC. T22-PE24-H6 and T22-DITOX-H6 CXCR4-dependent cytotoxic effect was evaluated in vitro in two different HNSCC cell lines. Both nanotoxins cell death mechanisms were assessed in HNSCC cell lines by phase-contrast microscopy, AnnexinV/ propidium iodide (PI) staining, lactate dehydrogenase (LDH) release assays, and western blotting. Nanotoxins antitumor effect in vivo was studied in a CXCR4 + HNSCC subcutaneous mouse model. Immunohistochemistry, histopathology, and toxicity analyses were used to evaluate both nanotoxins antitumor effect and possible treatment toxicity. GSMDE and CXCR4 expression in HNSCC patient tumor samples was also assessed by immunohistochemical staining. First, we found that both nanotoxins exhibit a potent CXCR4-dependent cytotoxic effect in vitro. Importantly, nanotoxin treatment triggered caspase-3/Gasdermin E (GSDME)-mediated pyroptosis. The activation of this alternative cell death pathway that differs from traditional apoptosis, becomes a promising strategy to bypass therapy resistance. In addition, T22-PE24-H6 and T22-DITOX-H6 displayed a potent antitumor effect in the absence of systemic toxicity in a CXCR4 + subcutaneous HNSCC mouse model. Lastly, GSDME was found to be overexpressed in tumor tissue from HNSCC patients, highlighting the relevance of this strategy. Altogether, our results show that T22-PE24-H6 and T22-DITOX-H6 represent a promising therapy for HNSCC patients. Remarkably, this is the first study showing that both nanotoxins are capable of activating caspase-3/GSDME-dependent pyroptosis, opening a novel avenue for HNSCC treatment. The online version contains supplementary material available at 10.1186/s13046-022-02267-8.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 + Diffuse Large B-Cell Lymphoma Cells

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Álamo, Patricia|||0000-0003-0510-5701
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limited by severe side effects. Therefore, we chose to improve the therapeutic window of the MTA monomethyl auristatin E developing a nanoconjugate, T22-AUR, that selectively targets the CXCR4 receptor, which is overexpressed in many DLBCL cells (CXCR4 +) and associated with poor prognosis. The T22-AUR specificity towards CXCR4 receptor was performed by flow cytometry in different DLBCL cell lines and running biodistribution assays in a subcutaneous mouse model bearing CXCR4 + DLBCL cells. Moreover, we determined T22-AUR cytotoxicity using cell viability assays, cell cycle analysis, DAPI staining and immunohistochemistry. Finally, the T22-AUR antineoplastic effect was evaluated in vivo in an extranodal CXCR4 + DLBCL mouse model whereas the toxicity analysis was assessed by histopathology in non-infiltrated mouse organs and by in vitro cytotoxic assays in human PBMCs. We demonstrate that the T22-AUR nanoconjugate displays CXCR4-dependent targeting and internalization in CXCR4 + DLBCL cells in vitro as well as in a subcutaneous DLBCL mouse model. Moreover, it shows high cytotoxic effect in CXCR4 + DLBCL cells, including induction of G2/M mitotic arrest, DNA damage, mitotic catastrophe and apoptosis. Furthermore, the nanoconjugate shows a potent reduction in lymphoma mouse dissemination without histopathological alterations in non-DLBCL infiltrated organs. Importantly, T22-AUR also exhibits lack of toxicity in human PBMCs. T22-AUR exerts in vitro and in vivo anticancer effect on CXCR4 + DLBCL cells without off-target toxicity. Thus, T22-AUR promises to become an effective therapy for CXCR4 + DLBCL patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Childhood maltreatment interacts with hypothalamic-pituitary-adrenal axis negative feedback and major depression, effects on cognitive performance

  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Labad, Javier|||0000-0003-2214-1886
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Segalàs, Cinto|||0000-0002-0959-0356
  • Real, Eva|||0000-0003-4523-1649
  • Ferrer, Alex|||0000-0002-3040-1177
  • Crespo, José M.
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
Background : Childhood maltreatment (CM) is associated with impaired hypothalamic-pituitary-adrenal (HPA) axis negative feedback and cognitive dysfunction, resembling those abnormalities linked to major depressive disorder (MDD). Objectives : We aimed to assess the potential modulating effects of MDD diagnosis or HPA axis function in the association between different types of CM and cognitive performance in adulthood. Methods : Sixty-eight MDD patients and 87 healthy controls were recruited. CM was assessed with the Childhood Trauma Questionnaire. We obtained three latent variables for neuropsychological performance (verbal memory, visual memory and executive function/processing speed) after running a confirmatory factor analysis with cognitive tests applied. Dexamethasone suppression test ratio (DSTR) was performed using dexamethasone 0.25 mg. Results : Different types of CM had different effects on cognition, modulated by MDD diagnosis and HPA axis function. Individuals with physical maltreatment and MDD presented with enhanced cognition in certain domains. The DSTR differentially modulated the association between visual memory and physical neglect or sexual abuse. Conclusions : HPA axis-related neurobiological mechanisms leading to cognitive impairment might differ depending upon the type of CM. Our results suggest a need for early assessment and intervention on cognition and resilience mechanisms in individuals exposed to CM to minimize its deleterious and lasting effects. HIGHLIGHTS • We studied the effects of childhood maltreatment (CM), HPA axis feedback (DST), and depression on cognition. • Different types of CM had a distinct impact on cognitive performance. • MDD diagnosis and DST modulated the association between CM and cognition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

AMYQ, An index to standardize quantitative amyloid load across PET tracers

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Aranha, Mateus|||0000-0001-9594-292X
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carrió, Ignasi|||0000-0003-1135-5352
  • Camacho, Valle|||0000-0003-0748-0847
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Positron emission tomography (PET) amyloid quantification methods require magnetic resonance imaging (MRI) for spatial registration and a priori reference region to scale the images. Furthermore, different tracers have distinct thresholds for positivity. We propose the AMYQ index, a new measure of amyloid burden, to overcome these limitations. We selected 18F-amyloid scans from ADNI and Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) with the corresponding T1-MRI. A subset also had neuropathological data. PET images were normalized, and the AMYQ was calculated based on an adaptive template. We compared AMYQ with the Centiloid scale on clinical and neuropathological diagnostic performance. AMYQ was related with amyloid neuropathological burden and had excellent diagnostic performance to discriminate controls from patients with Alzheimer's disease (AD) (area under the curve [AUC] = 0.86). AMYQ had a high agreement with the Centiloid scale (intraclass correlation coefficient [ICC] = 0.88) and AUC between 0.94 and 0.99 to discriminate PET positivity when using different Centiloid cutoffs. AMYQ is a new MRI-independent index for standardizing and quantifying amyloid load across tracers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of a psychosocial intervention at one-year follow-up in a PREDIMED-plus sample with obesity and metabolic syndrome

  • Mallorquí-Bagué, Núria|||0000-0003-1434-3162
  • Lozano Madrid, María|||0000-0003-3833-317X
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Forcano, Laura|||0000-0002-8478-1451
  • Díaz-López, Andrés|||0000-0002-7500-5629
  • Galera, Ana
  • Fernández-Carrión, Rebeca
  • Granero, Roser|||0000-0001-6308-3198
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Corella, Dolores|||0000-0002-2366-4104
  • Pintó, Xavier|||0000-0002-2216-2444
  • Cuenca-Royo, Aida|||0000-0001-8551-5457
  • Bulló, Mònica|||0000-0002-0218-7046
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
This study examines if overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms, and if these variables could be modified after 1 year of a multimodal intervention (diet, physical activity, psychosocial support). 342 adults (55-75 years) with overweight/obesity and metabolic syndrome (MetS) from the PREDIMED-Plus Cognition study were randomized to the intervention or to the control group (lifestyle recommendations). Cognitive and psychopathological assessments were performed at baseline and after 1-year follow-up. At baseline, higher impulsivity was linked to higher food addiction and depressive symptoms, but not to body mass index (BMI). Food addiction not only predicted higher BMI and depressive symptoms, but also achieved a mediational role between impulsivity and BMI/depressive symptoms. After 1 year, patients in both groups reported significant decreases in BMI, food addiction and impulsivity. BMI reduction and impulsivity improvements were higher in the intervention group. Higher BMI decrease was achieved in individuals with lower impulsivity. Higher scores in food addiction were also related to greater post-treatment impulsivity. To conclude, overweight/obesity are related to higher impulsivity, food addiction and depressive symptoms in mid/old age individuals with MetS. Our results also highlight the modifiable nature of the studied variables and the interest of promoting multimodal interventions within this population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lifetime Weight Course as a Phenotypic Marker of Severity and Therapeutic Response in Patients with Eating Disorders

  • Agüera, Zaida|||0000-0003-4453-4939
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Baenas Soto, Isabel Maria|||0000-0001-7415-0616
  • Granero, Roser|||0000-0001-6308-3198
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Treasure, Janet|||0000-0003-0871-4596
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
The association between lifetime weight fluctuations and clinical characteristics has been widely studied in populations with eating disorders (ED). However, there is a lack of literature examining the potential role of weight course as a transdiagnostic factor in ED so far. Therefore, the aim of this study is to compare ED severity and treatment outcomes among four specific BMI profiles based on BMI-trajectories across the lifespan: (a) persistent obesity (OB-OB; (n = 74)), (b) obesity in the past but currently in a normal weight range (OB-NW; n = 156), (c) normal weight throughout the lifespan (NW-NW; n = 756), and (d) current obesity but previously at normal weight (NW-OB; n = 314). Lifetime obesity is associated with greater general psychopathology and personality traits such as low persistence and self-directedness, and high reward dependence. Additionally, greater extreme weight changes (NW-OB and OB-NW) were associated with higher psychopathology but not with greater ED severity. Higher dropout rates were found in the OB-OB group. These results shed new light on the BMI trajectory as a transdiagnostic feature playing a pivotal role in the severity and treatment outcome in patients with ED.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis

  • Molina-García, Mariola
  • Fraguas, David|||0000-0002-7931-2933
  • del Rey-Mejías, Ángel|||0000-0003-1690-3215
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Vieta, Eduard|||0000-0002-0548-0053
  • Baeza, Inmaculada|||0000-0003-2611-5781
  • Mané, Anna|||0000-0003-2127-349X
  • Cuesta, Manuel J.|||0000-0003-0250-5718
  • de la Serna, Elena|||0000-0002-7869-9881
  • Payá, Beatriz
  • Zorrilla, Iñaki|||0000-0001-6444-8208
  • Arango, Celso|||0000-0003-3382-4754
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Rapado-Castro, Marta|||0000-0001-8484-6051
  • Parellada, Mara|||0000-0001-7977-3601
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neuropsychological Learning Deficits as Predictors of Treatment Outcome in Patients with Eating Disorders

  • Lucas Adell, Ignacio|||0000-0001-9426-5082
  • Miranda-Olivos, Romina|||0000-0003-2360-5830
  • Testa, Giulia|||0000-0003-4200-8062
  • Granero, Roser|||0000-0001-6308-3198
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Eating disorders (EDs) are severe psychiatric illnesses that require individualized treatments. Decision-making deficits have been associated with EDs. Decision-making learning deficits denote a lack of strategies to elaborate better decisions that can have an impact on recovery and response to treatment. This study used the Iowa Gambling Task (IGT) to investigate learning differences related to treatment outcome in EDs, comparing between patients with a good and bad treatment outcome and healthy controls. Likewise, the predictive role of impaired learning performance on therapy outcome was explored. Four hundred twenty-four participants (233 ED patients and 191 healthy controls) participated in this study. Decision making was assessed using the Iowa Gambling Task before any psychological treatment. All patients received psychological therapy, and treatment outcome was evaluated at discharge. Patients with bad outcome did not show progression in the decision-making task as opposed to those with good outcome and the healthy control sample. Additionally, learning performance in the decision-making task was predictive of their future outcome. The severity of learning deficits in decision making may serve as a predictor of the treatment. These results may provide a starting point of how decision-making learning deficits are operating as dispositional and motivational factors on responsiveness to treatment in EDs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Montal, Victor|||0000-0002-5714-9282
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Garzón, Diana
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Camacho, Valle|||0000-0003-0748-0847
  • Medrano-Martorell, Santiago|||0000-0002-6586-7284
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Blennow, Kaj|||0000-0002-1890-4193
  • Fortea, Juan|||0000-0002-1340-638X
  • Zetterberg, Henrik|||0000-0003-3930-4354
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS. Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease

  • Giménez, Sandra|||0000-0001-8031-2319
  • Farre, Ariadna
  • Morente, Fátima
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Gutiérrez, Marta
  • Clos, Susana|||0000-0001-5350-821X
  • Fernández-Arcos, Ana
  • Blanco, Marta
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Asensio, Amparo
  • Benejam, Bessy|||0000-0002-6789-8615
  • Batista, Mar
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fortuna Gutiérrez, Ana Mª|||0000-0002-3619-1609
  • Fortea, Juan|||0000-0002-1340-638X
  • Mayos, Merce|||0000-0003-3972-3671
.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Standardized comparison of cardiovascular risk factors prevalence in spanish women and men living with hiv and in the general population

  • Camps-Vilaró, Anna|||0000-0001-9644-8421
  • Pérez-Fernández, Silvia|||0000-0002-9756-0092
  • Subirana, Isaac|||0000-0003-1676-0197
  • Teira, R.
  • Estrada, Vicente|||0000-0002-7795-5986
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Degano, Irene R.|||0000-0003-1914-6934
  • Marrugat, Jaume|||0000-0003-3320-554X
People living with HIV (PLWH) have an increased risk of cardiovascular (CV) disease, likely due to a higher prevalence of CV risk factors. We compared the age-standardized prevalence and management of CV risk factors in PLWH to that of the general population in Spain. Blood pressure, lipid, glucose, and anthropometric profiles were cross-sectionally compared along with the treatment of hypertension, dyslipidemia, and diabetes in a general population cohort and a PLWH cohort. Prevalence rates were standardized by the direct method by 10-year age groups in European standard populations and stratified by gender. We included 47,593 individuals aged 35 to 74 years, 28,360 from the general population cohort and 19,233 from the PLWH cohort. Compared to the general population, PLWH had a higher concentration of triglycerides (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex-specific metabolic pathways were associated with alzheimer's disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

  • Xu, Jin
  • Green, Becki|||0000-0002-0513-5188
  • Kim, Min|||0000-0002-8769-4804
  • Lord, Jodie|||0000-0003-2955-7809
  • Ebshiana, Amera
  • Westwood, Sarah|||0000-0003-0506-7813
  • Baird, Alison
  • Nevado-Holgado, Alejo|||0000-0001-9276-2720
  • Shi, Liu|||0000-0003-1752-0419
  • Hye, Abdul|||0000-0003-2237-4823
  • Snowden, Stuart|||0000-0002-9419-5819
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • ten Kate, Mara|||0000-0002-8290-8543
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gabel, Silvy
  • Meersmans, Karen
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • De Roeck, Ellen
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Bordet, Régis|||0000-0003-3916-6422
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Kettunen, Petronella|||0000-0002-2510-3423
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Verhey, Frans R. J.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Peyratout, Gwendoline
  • Tainta, Mikel|||0000-0003-0624-1211
  • Johannsen, Peter
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Froelich, Lutz|||0000-0003-1494-0813
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Wallin, Anders|||0000-0001-9506-0513
  • Popp, Julius|||0000-0002-0068-0312
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Bertram, Lars|||0000-0002-0108-124X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Lovestone, Simon|||0000-0003-0473-4565
  • Proitsi, Petroula|||0000-0002-2553-6974
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. Methods: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, cerebrospinal fluid (CSF) biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites' discriminatory performance in AD. Results: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (area under curve (AUC) = 0.83, standard error (SE) = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046). Conclusions: metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, were associated to females, paving the way to personalised treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Food addiction and lifetime alcohol and illicit drugs use in specific eating disorders

  • Miranda-Olivos, Romina|||0000-0003-2360-5830
  • Agüera, Zaida|||0000-0003-4453-4939
  • Granero, Roser|||0000-0001-6308-3198
  • Vergeer, Rhianna R.
  • Dieguez, Carlos|||0000-0002-0919-4337
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Gearhardt, Ashley N.|||0000-0003-3843-5731
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Food addiction (FA) and substance use (SU) have frequently been reported in patients with eating disorders (EDs). Our study aimed to assess the prevalence rates of FA and/or lifetime problematic alcohol and illicit drug use among patients with specific ED, such as: bulimia nervosa (BN), binge eating disorder (BED), and other specified feeding and eating disorder (OSFED). We sought to identify clinical, psychopathological, and personality profiles involved in these addictive behavior-based phenotypes. The total sample was 527 patients (176 BN, 115 BED, and 236 OSFED). FA was assessed through the Yale Food Addiction Scale 2.0. To determine lifetime SU, a semi-structured clinical interview was carried out. Patients with BN had the highest rates of FA both with and without SU. No gender differences were obtained for the prevalence of current FA and/or lifetime SU. Patients reporting at least one addictive-related behavior exhibited increased clinical severity compared to those who reported none. Increased impulsivity (such as high lack of premeditation, sensation seeking, and positive urgency) and low self-directedness were differentiating factors for presenting one or two addictive behaviors. Overall, patients presenting with at least one addictive-like behavior reported a poorer clinical status than those without. Also, patients with FA and SU exhibited a more dysfunctional profile characterized by high impulsivity and low self-directedness. These findings would support the need for targeted treatments to reduce impulsivity and increase self-directedness, especially in patients with any addictive-related behavior, as a step towards improving their treatment outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Males and females with first episode psychosis present distinct profiles of social cognition and metacognition

  • Ferrer-Quintero, Marta|||0000-0002-7935-9424
  • Fernández, D.
  • López-Carrilero, Raquel|||0000-0003-4110-794X
  • Birulés, Irene|||0000-0001-6518-7310
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Lorente Rovira, Esther
  • Luengo, Ana
  • Díaz-Cutraro, L.|||0000-0003-3985-2780
  • Verdaguer-Rodríguez, Marina|||0000-0001-9910-1220
  • García-Mieres, Helena|||0000-0002-2813-1737
  • Gutiérrez-Zotes, Alfonso|||0000-0002-4858-1487
  • Grasa, Eva|||0000-0003-1100-7489
  • Pousa Tomàs, Esther|||0000-0003-4423-6739
  • Huerta-Ramos, Elena
  • Pélaez, T.
  • Barrigón, María Luisa|||0000-0002-2497-6353
  • Gómez-Benito, Juana|||0000-0002-4280-3106
  • González-Higueras, Fermín|||0000-0002-0826-5981
  • Ruiz Delgado, Isabel
  • Cid, Joan|||0000-0001-5445-4508
  • Moritz, Steffen|||0000-0001-8601-0143
  • Sevilla-Llewellyn-Jones, J.
  • Ochoa, Susana|||0000-0001-6792-1080
Deficits in social cognition and metacognition impact the course of psychosis. Sex diferences in social cognition and metacognition could explain heterogeneity in psychosis. 174 (58 females) patients with frst-episode psychosis completed a clinical, neuropsychological, social cognitive, and metacognitive assessment. Subsequent latent profle analysis split by sex yielded two clusters common to both sexes (a Homogeneous group, 53% and 79.3%, and an Indecisive group, 18.3% and 8.6% of males and females, respectively), a specifc male profle characterized by presenting jumping to conclusions (28.7%) and a specifc female profle characterized by cognitive biases (12.1%). Males and females in the homogeneous profle seem to have a more benign course of illness. Males with jumping to conclusions had more clinical symptoms and more neuropsychological defcits. Females with cognitive biases were younger and had lower self-esteem. These results suggest that males and females may beneft from specifc targeted treatment and highlights the need to consider sex when planning interventions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Emotional regulation in eating disorders and gambling disorder, A transdiagnostic approach

  • Munguía Godínez, Jazmín Lucero|||0000-0002-9751-810X
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Granero, Roser|||0000-0001-6308-3198
  • Baenas Soto, Isabel Maria|||0000-0001-7415-0616
  • Agüera, Zaida|||0000-0003-4453-4939
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Codina, Ester|||0000-0002-0848-0614
  • Pino Gutiérrez, Amparo del|||0000-0002-2854-9850
  • Testa, Giulia|||0000-0003-4200-8062
  • Treasure, Janet|||0000-0003-0871-4596
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Difficulties in Emotion Regulation (ER) are related to the etiology and maintenance of several psychological disorders, including Eating Disorders (ED) and Gambling Disorder (GD). This study explored the existence of latent empirical groups between both disorders, based on ER difficulties and considering a set of indicators of personality traits, the severity of the disorder, and psychopathological distress. The sample included 1,288 female and male participants, diagnosed with ED (n = 906) and GD (n = 382). Two-step clustering was used for the empirical classification, while analysis of variance and chi-square tests were used for the comparison between the latent groups. Three empirical groups were identified, from the most disturbed ER profile (Subgroup 1) to the most functional (Subgroup 3). The ER state showed a linear relationship with the severity of each disorder and the psychopathological state. Different personality traits were found to be related to the level of emotion dysregulation. In this study, three distinct empirical groups based on ER were identified across ED and GD, suggesting that ER is a transdiagnostic construct. These findings may lead to the development of common treatment strategies and more tailored approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome

  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Muñoz, Laia|||0000-0003-0578-3094
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Wilson, Liam Reese
  • Annus, Tiina
  • Osorio, R.S.
  • Videla, S.
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony|||0000-0003-4107-130X
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. Objective: To investigate the association of the APOE ϵ4 allele with clinical and multimodal biomarkers of AD in adults with DS. Design, Setting, and Participants: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE ϵ4 allele carriers or noncarriers. Main Outcomes and Measures: Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: Aβ1-42, Aβ1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE ϵ4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume. Results: Of the 464 adults with DS included in the study, 97 (20.9%) were APOE ϵ4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P =.56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE ϵ4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P =.02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ϵ4 allele carriers. Conclusions and Relevance: In this study, the APOE ϵ4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Microvesicles carrying LRP5 induce macrophage polarization to an anti-inflammatory phenotype

  • Luquero, Aureli|||0000-0002-1104-5963
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Crespo Asensio, Javier
  • Badimon, Lina|||0000-0002-9162-2459
  • Borrell-Pages, Maria|||0000-0002-1759-9756
Microvesicles (MV) contribute to cell-to-cell communication through their transported proteins and nucleic acids. MV, released into the extracellular space, exert paracrine regulation by modulating cellular responses after interaction with near and far target cells. MV are released at high concentrations by activated inflammatory cells. Different subtypes of human macrophages have been characterized based on surface epitopes being CD16 macrophages associated with anti-inflammatory phenotypes. We have previously shown that low-density lipoprotein receptor-related protein 5 (LRP5), a member of the LDLR family that participates in lipid homeostasis, is expressed in macrophage CD16 with repair and survival functions. The goal of our study was to characterize the cargo and tentative function of macrophage-derived MV, whether LRP5 is delivered into MV and whether these MV are able to induce inflammatory cell differentiation to a specific CD16 or CD16 phenotype. We show, for the first time, that lipid-loaded macrophages release MV containing LRP5. LDL loading induces increased expression of macrophage pro-inflammatory markers and increased release of MV containing pro-inflammatory markers. Conditioning of fresh macrophages with MV released by Lrp5-silenced macrophages induced the transcription of inflammatory genes and reduced the transcription of anti-inflammatory genes. Thus, MV containing LRP5 induce anti-inflammatory phenotypes in macrophages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique

  • Amoretti, Silvia|||0000-0001-6017-2734
  • Verdolini, Norma|||0000-0001-9488-2881
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Rabelo-da-Ponte, Francisco Diego|||0000-0001-9016-2414
  • Cuesta, Manuel J.|||0000-0003-0250-5718
  • Pina-Camacho, Laura|||0000-0003-1960-6443
  • Gomez-Ramiro, Marta|||0000-0002-3463-0866
  • Cámara, Concepción de la|||0000-0003-2284-7862
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Vieta, Eduard|||0000-0002-0548-0053
  • de la Serna, Elena|||0000-0002-7869-9881
  • Mané, Anna|||0000-0003-2127-349X
  • Solé, Brisa|||0000-0003-1673-8248
  • Carvalho, André F.
  • Serra-Navarro, Maria|||0000-0002-9736-4630
  • Bernardo, Miquel|||0000-0001-8748-6717
The extreme variability in symptom presentation reveals that individuals diagnosed with a first-episode psychosis (FEP) may encompass different sub-populations with potentially different illness courses and, hence, different treatment needs. Previous studies have shown that sociodemographic and family environment factors are associated with more unfavorable symptom trajectories. The aim of this study was to examine the dimensional structure of symptoms and to identify individuals' trajectories at early stage of illness and potential risk factors associated with poor outcomes at follow-up in non-affective FEP. One hundred and forty-four non-affective FEP patients were assessed at baseline and at 2-year follow-up. A Principal component analysis has been conducted to identify dimensions, then an unsupervised machine learning technique (fuzzy clustering) was performed to identify clinical subgroups of patients. Six symptom factors were extracted (positive, negative, depressive, anxiety, disorganization and somatic/cognitive). Three distinct clinical clusters were determined at baseline: mild; negative and moderate; and positive and severe symptoms, and five at follow-up: minimal; mild; moderate; negative and depressive; and severe symptoms. Receiving a low-dose antipsychotic, having a more severe depressive symptomatology and a positive family history for psychiatric disorders were risk factors for poor recovery, whilst having a high cognitive reserve and better premorbid adjustment may confer a better prognosis. The current study provided a better understanding of the heterogeneous profile of FEP. Early identification of patients who could likely present poor outcomes may be an initial step for the development of targeted interventions to improve illness trajectories and preserve psychosocial functioning.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer's disease

  • Rujeedawa, Tanzil|||0000-0002-7089-1684
  • Carrillo Félez, Eva
  • Clare, Isabel C.H.|||0000-0002-5385-008X
  • Fortea, Juan|||0000-0002-1340-638X
  • Strydom, Andre
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Coppus, Antonia
  • Levin, Johannes|||0000-0001-5092-4306
  • Zaman, Shahid
The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's disease in (DSAD) and Autosomal Dominant Alzheimer's disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease

  • Benejam, Bessy|||0000-0002-6789-8615
  • Aranha, Mateus|||0000-0001-9594-292X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Videla, Sebastián|||0000-0001-5049-1379
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Methods: Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Results: Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Conclusions: Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Nigro, Salvatore
  • Vandevrede, Lawren
  • Falgàs, Neus|||0000-0002-3404-2765
  • Heuer, Hilary W.
  • Painous, Cèlia|||0000-0002-7027-3093
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Montal, Victor|||0000-0002-5714-9282
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Quattrone, Andrea
  • Perry, David C.
  • Gorno-Tempini, Maria Luisa
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Grinberg, Lea T.
  • Spina, Salvatore
  • La Joie, Renaud
  • Rabinovici, Gil D.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Rojas, Julio C.|||0000-0002-1308-646X
  • Seeley, William W.
  • Boxer, Adam
Importance: The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective: To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants: This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures: The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results: Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance: In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Alzheimer Disease with Life Expectancy in People with Down Syndrome

  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Garzón Chavez, Diana
  • Klitgaard Christensen, Maria
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Plana Ripoll, Oleguer|||0000-0002-6470-7465
  • Rasmussen, Sonja A.
  • Roqué i Figuls, Marta|||0000-0003-0043-1364
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Benejam, Bessy|||0000-0002-6789-8615
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Padilla, Concepción|||0000-0003-4102-6787
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Fernández, Susana|||0000-0002-9777-1156
  • Belbin, Olivia|||0000-0002-6109-6371
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fortea, Juan|||0000-0002-1340-638X
Importance: People with Down syndrome have a high risk of developing Alzheimer disease dementia. However, penetrance and age at onset are considered variable, and the association of this disease with life expectancy remains unclear because of underreporting in death certificates. Objective: To assess whether the variability in symptom onset of Alzheimer disease in Down syndrome is similar to autosomal dominant Alzheimer disease and to assess its association with mortality. Design, Setting, and Participants: This study combines a meta-analysis with the assessment of mortality data from US death certificates (n = 77347 case records with a International Classification of Diseases code for Down syndrome between 1968 to 2019; 37900 [49%] female) and from a longitudinal cohort study (n = 889 individuals; 46% female; 3.2 [2.1] years of follow-up) from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI). Main Outcomes and Measures: A meta-analysis was conducted to investigate the age at onset, age at death, and duration of Alzheimer disease dementia in Down syndrome. PubMed/Medline, Embase, Web of Science, and CINAHL were searched for research reports, and OpenGray was used for gray literature. Studies with data about the age at onset or diagnosis, age at death, and disease duration were included. Pooled estimates with corresponding 95% CIs were calculated using random-effects meta-analysis. The variability in disease onset was compared with that of autosomal dominant Alzheimer disease. Based on these estimates, a hypothetical distribution of age at death was constructed, assuming fully penetrant Alzheimer disease. These results were compared with real-world mortality data. Results: In this meta-analysis, the estimate of age at onset was 53.8 years (95% CI, 53.1-54.5 years; n = 2695); the estimate of age at death, 58.4 years (95% CI, 57.2-59.7 years; n = 324); and the estimate of disease duration, 4.6 years (95% CI, 3.7-5.5 years; n = 226). Coefficients of variation and 95% prediction intervals of age at onset were comparable with those reported in autosomal dominant Alzheimer disease. US mortality data revealed an increase in life expectancy in Down syndrome (median [IQR], 1 [0.3-16] years in 1968 to 57 [49-61] years in 2019), but with clear ceiling effects in the highest percentiles of age at death in the last decades (90th percentile: 1990, age 63 years; 2019, age 65 years). The mortality data matched the limits projected by a distribution assuming fully penetrant Alzheimer disease in up to 80% of deaths (corresponding to the highest percentiles). This contrasts with dementia mentioned in 30% of death certificates but is in agreement with the mortality data in DABNI (78.9%). Important racial disparities persisted in 2019, being more pronounced in the lower percentiles (10th percentile: Black individuals, 1 year; White individuals, 30 years) than in the higher percentiles (90th percentile: Black individuals, 64 years; White individuals, 66 years). Conclusions and Relevance: These findings suggest that the mortality data and the consistent age at onset were compatible with fully penetrant Alzheimer disease. Lifespan in persons with Down syndrome will not increase until disease-modifying treatments for Alzheimer disease are available.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characteristics of subjective cognitive decline associated with amyloid positivity

  • Janssen, Olin|||0000-0002-8341-0958
  • Jansen, Willemijn J.
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Boada, Mercè|||0000-0003-2617-3009
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Gabryelewicz, Tomasz
  • Fladby, Tormod|||0000-0002-9984-9797
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Villeneuve, Sylvia
  • Hort, Jakub|||0000-0002-1080-3726
  • Epelbaum, Stéphane
  • Lleó, Alberto|||0000-0002-2568-5478
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Landau, Susan
  • Popp, Julius|||0000-0002-0068-0312
  • Wallin, Anders|||0000-0001-9506-0513
  • Scheltens, Philip|||0000-0002-1046-6408
  • Rikkert, Marcel Olde|||0000-0003-1397-1677
  • Snyder, Peter J.|||0000-0003-0555-4654
  • Rowe, Chris
  • Chételat, G.|||0000-0002-4889-7932
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Marquié, Marta|||0000-0002-0660-0950
  • Chipi, Elena
  • Wolfsgruber, Steffen
  • Heneka, Michael|||0000-0003-4996-1630
  • Boecker, Henning|||0000-0003-2346-0598
  • Peters, Oliver|||0000-0003-0568-2998
  • Jarholm, Jonas
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Poirier, Judes
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Cerman, Jiri
  • Dubois, Bruno
  • Teichmann, Marc
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Ebenau, Jarith
  • Pocnet, Cornelia
  • Eckerström, Marie
  • Thompson, Louisa
  • Villemagne, Victor
  • Buckley, Rachel|||0000-0002-5356-5537
  • Burnham, Samantha
  • Delarue, Marion
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Wallin, Åsa K.
  • Ramakers, Inez
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Hampel, Harald
  • Spiru, Luiza
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Ossenkoppele, Rik
  • Verhey, Frans
  • Jessen, Frank
  • Visser, Pieter Jelle|||0000-0001-8008-9727
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Regional, circuit and network heterogeneity of brain abnormalities in psychiatric disorders

  • Segal, Ashlea|||0000-0002-7451-6195
  • Parkes, Linden|||0000-0002-9329-7207
  • Aquino, Kevin
  • Kia, Seyed Mostafa
  • Wolfers, Thomas
  • Franke, Barbara|||0000-0003-4375-6572
  • Hoogman, Martine|||0000-0002-1261-7628
  • Beckmann, Christian F.
  • Westlye, Lars T.|||0000-0001-8644-956X
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Zalesky, Andrew|||0000-0003-2298-9908
  • Harrison, Ben J.
  • Davey, Christopher|||0000-0003-1431-3852
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Tiego, Jeggan|||0000-0001-7835-6398
  • Yücel, Murat|||0000-0002-4705-452X
  • Braganza, Leah
  • Suo, Chao
  • Berk, Michael
  • Cotton, Sue
  • Bellgrove, Mark A.|||0000-0003-0186-8349
  • Marquand, Andre F.|||0000-0001-5903-203X
  • Fornito, Alex|||0000-0003-0866-3477
The substantial individual heterogeneity that characterizes people with mental illness is often ignored by classical case-control research, which relies on group mean comparisons. Here we present a comprehensive, multiscale characterization of the heterogeneity of gray matter volume (GMV) differences in 1,294 cases diagnosed with one of six conditions (attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, depression, obsessive-compulsive disorder and schizophrenia) and 1,465 matched controls. Normative models indicated that person-specific deviations from population expectations for regional GMV were highly heterogeneous, affecting the same area in <7% of people with the same diagnosis. However, these deviations were embedded within common functional circuits and networks in up to 56% of cases. The salience-ventral attention system was implicated transdiagnostically, with other systems selectively involved in depression, bipolar disorder, schizophrenia and attention-deficit/hyperactivity disorder. Phenotypic differences between cases assigned the same diagnosis may thus arise from the heterogeneous localization of specific regional deviations, whereas phenotypic similarities may be attributable to the dysfunction of common functional circuits and networks. A new brain mapping approach tailored to individual people reveals that volume changes in psychiatric illness occur in highly variable locations across individuals, but that these differences often aggregate within common brain systems.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of mHealth technology on adherence to healthy PA after stroke, a randomized study

  • Grau-Pellicer, Montserrat|||0000-0003-2904-9011
  • F. Lalanza, Jaume|||0000-0003-2481-2188
  • Jovell-Fernández, E.
  • Capdevila Ortís, Lluís|||0000-0002-7319-4745
Background: Physical activity (PA) is a key health behavior in people with stroke including risk reduction of recurrent stroke. Despite the beneficial effects of PA, many community-dwelling stroke survivors are physically inactive. Information and communication technologies are emerging as a possible method to promote adherence to PA. Objective: The aim of this study is to investigate the effectiveness of a mobile-health (mHealth) App in improving levels of PA. Methods: Forty-one chronic stroke survivors were randomized into an intervention group (IG) n=24 and a control group (CG) n=17. Participants in the IG were engaged in the Multimodal Rehabilitation Program (MMRP) that consisted on supervising adherence to PA through a mHealth app, participating in an 8-week rehabilitation program that included: aerobic, task-oriented, balance and stretching exercises. Participants also performed an ambulation program at home. The CG received a conventional rehabilitation program. Outcome variables were: adherence to PA, (walking and sitting time/day), walking speed (10MWT); walking endurance (6MWT); risk of falling (TUG); ADLs (Barthel); QoL (Eq-5D5L) and participant's satisfaction. Results: At the end of the intervention, community ambulation increased more in IG (38.95 min; SD: 20.37) than in the CG (9.47 min; SD: 12.11) (p≤.05). Sitting time was reduced by 2.96 (SD 2.0) hours/day in the IG and by 0.53 (SD 0.24) hours in the CG (p≤.05). Conclusions: The results suggest that mHealth technology provides a novel way to promote adherence to home exercise programs post stroke. However, frequent support and guidance of caregiver is required to ensure the use of mobile devices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Food addiction in anorexia nervosa, Implications for the understanding of crossover diagnosis

  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Lucas Adell, Ignacio|||0000-0001-9426-5082
  • Munguía Godínez, Jazmín Lucero|||0000-0002-9751-810X
  • Camacho-Barcia, Lucía|||0000-0002-5989-936X
  • Giménez, Mónica|||0000-0003-2757-0145
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Granero, Roser|||0000-0001-6308-3198
  • Solé-Morata, Neus|||0000-0003-0433-0843
  • Gearhardt, Ashley N.|||0000-0003-3843-5731
  • Dieguez, Carlos|||0000-0002-0919-4337
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Food addiction (FA) construct was introduced to reflect abnormal eating patterns that resemble behavioural ones found in substance use disorders. FA has been barely explored in anorexia nervosa (AN). This study evaluated FA occurrence and associated factors in a sample of patients with AN, distinguishing between restrictive and binge-purging subtypes and focussing on the influence of FA in the crossover diagnosis between them. A sample of 116 patients with AN admitted for treatment seeking at an Bellvitge Hospital Eating Disorders Unit were included (72 restrictive [AN-R]; 44 binge-purge AN [AN-BP]), and eating-related, personality and psychopathological variables were assessed. Most participants were women (92.2%), mean age 27.1 years old (SD = 10.5). FA was more prevalent in patients with AN-BP compared to the AN-R group (75.0% and 54.2%, respectively). The patients with AN-R FA+, presented more similar ED symptomatology, general psychopathology and personality traits, with the AN-BP patients, than with the AN-R FA-. Patients with AN-R FA+, exhibit more similarities with the AN-BP subgroup than with the AN-R FA-. Thus, it is possible to hypothesise that the presence of FA might be an indicator of the possible crossover from AN-R to AN-BP.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Mitjans, M.
  • Hartman, CA.
  • Artigas, M. Soler
  • Demontis, Ditte|||0000-0001-9124-2766
  • Larsson, Henrik
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Kuntsi, J.
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Børglum, AD.
  • Reif, Andreas|||0000-0002-0992-634X
  • Franke, Barbara|||0000-0003-4375-6572
  • Cormand, Bru|||0000-0001-5318-4382
Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

  • Guillén, Núria|||0000-0002-1341-9834
  • Contador, José
  • Buongiorno, Mariateresa
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Culell, Natalia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Piñol-Ripoll, Gerard
  • Carnes-Vendrell, Anna
  • Ispierto, María Lourdes|||0000-0002-1837-9675
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Balasa, Mircea|||0000-0002-1795-4228
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta (Aβ, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ/Aβ (n = 155), 88% for pTau181/Aβ (n = 94) and 82% for tTau/Aβ (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ/Aβ was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Null hypothesis significance tests, a misleading approach to scientific knowledge, some implications for eating disorders research

  • Granero, Roser|||0000-0001-6308-3198
  • Treasure, Janet|||0000-0003-0871-4596
  • Claes, Laurence|||0000-0002-2287-3158
  • Favaro, Andrea
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Karwautz, Andreas|||0000-0001-9053-998X
  • Le Grange, Daniel|||0000-0001-7293-9496
  • Tchanturia, Kate|||0000-0001-8988-3265
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cognitive and clinical gender-related differences among binge-spectrum eating disorders, analysis of therapy response predictors

  • Mallorquí-Bagué, Núria|||0000-0003-1434-3162
  • Lozano Madrid, María|||0000-0003-3833-317X
  • Granero, Roser|||0000-0001-6308-3198
  • Mestre-Bach, Gemma|||0000-0001-5345-0484
  • Vintró Alcaraz, Cristina|||0000-0001-9453-8810
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
Objective: This study assessed gender-related differences in executive functions (decision-making, inhibitory control and cognitive flexibility), personality traits and psychopathological symptoms in binge-spectrum eating disorders (EDs). Secondly, we aimed to separately explore the predictive value of gender and executive functions in treatment outcome. Method: A battery of self-reported and neurocognitive measures were answered by a sample of 85 patients (64 females) diagnosed with a binge-spectrum ED (41 BN; 44 binge eating disorder). Results: Data showed gender-related differences in executive functioning, displaying women lower inhibitory control and lower cognitive flexibility than men. Regarding personality traits and psychopathology symptoms, women presented higher reward dependence and cooperativeness, as well as more drive for thinness, body dissatisfaction, bulimia, and somatisation symptoms than men. Finally, worse executive functioning, particularly having lower ability in concept formation seems to predict worse treatment outcomes and dropout in these patients. Conclusions: We described gender specific neuropsychological, personality and psychopathological impairments in patients with binge-spectrum EDs. Moreover, difficulties in executive functioning might have an impact on treatment response, since patients with a lower ability in concept formation are less likely to benefit from treatment. The present results can help improving current treatment approaches by tackling gender and individual differences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Where does purging disorder lie on the symptomatologic and personality continuum when compared to other eating disorder subtypes?, implications for the DSM

  • Krug, Isabel|||0000-0002-5275-3595
  • Giles, Sarah
  • Granero, Roser|||0000-0001-6308-3198
  • Agüera, Zaida|||0000-0003-4453-4939
  • Sánchez Díaz, Isabel María|||0000-0001-5874-8204
  • Sánchez González, Jéssica|||0000-0002-9327-0100
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
OBJECTIVES: To assess the clinical significance and distinctiveness of purging disorder (PD) from other eating disorder (ED) diagnoses. METHOD: Participants included 3127 women consecutively admitted to an ED treatment centre (246 PD, 465 anorexia nervosa restrictive [AN-R], 327 AN-binge purging [AN-BP], 1436 bulimia nervosa [BN], 360 binge eating disorder [BED], 177 atypical AN and 116 unspecified feeding or eating disorder [UFED]) who were diagnosed according to DSM-5 criteria. Additionally, 822 control participants were recruited from the community. All participants completed measures assessing ED symptoms (EDI-2), general psychopathology (SCL-90-R) and personality (TCI-R). RESULTS: Patients with PD, when compared to controls, scored significantly higher on the EDI-2 and SCL-90-R, and most TCI-R dimensions. Most of the significant differences between PD and the other ED diagnoses emerged between PD and AN-R, followed by Atypical-AN, UFED, AN-BP and BED, with patients with PD typically reporting higher scores on the EDI-2 and SCL-90-R subscales. Significant differences between PD and BN were also present, but to a lesser extent. The findings for personality varied amongst the different ED diagnoses. CONCLUSIONS: PD is a clinically significant disorder, which seems to be more similar to BN than it is to AN and the other ED subtypes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder

  • Walters, Raymond K.
  • Rajagopal, Veera M.
  • Waldman, Irwin D.
  • Grove, Jakob
  • Als, Thomas D.
  • Ribases Haro, Marta
  • Demontis, Ditte
TDAH; Genoma; Estudios de asociación amplia, ADHD; Genome; Wide association studies, TDAH; Genoma; Estudis d'associació ample, Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood psychiatric disorder often comorbid with disruptive behavior disorders (DBDs). Here, we report a GWAS meta-analysis of ADHD comorbid with DBDs (ADHD + DBDs) including 3802 cases and 31,305 controls. We identify three genome-wide significant loci on chromosomes 1, 7, and 11. A meta-analysis including a Chinese cohort supports that the locus on chromosome 11 is a strong risk locus for ADHD + DBDs across European and Chinese ancestries (rs7118422, P = 3.15×10−10, OR = 1.17). We find a higher SNP heritability for ADHD + DBDs (h2SNP = 0.34) when compared to ADHD without DBDs (h2SNP = 0.20), high genetic correlations between ADHD + DBDs and aggressive (rg = 0.81) and anti-social behaviors (rg = 0.82), and an increased burden (polygenic score) of variants associated with ADHD and aggression in ADHD + DBDs compared to ADHD without DBDs. Our results suggest an increased load of common risk variants in ADHD + DBDs compared to ADHD without DBDs, which in part can be explained by variants associated with aggressive behavior.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Gut microbiota signature in treatment-naïve attention-deficit/hyperactivity disorder

  • Richarte Fernández, Vanesa
  • Sanchez Mora, Cristina P
  • Corrales De la Cruz, Montserrat
  • Fadeuilhe Grau, Christian
  • Vilar Ribo, Laura
  • Arribas Garcia, Lorena
  • Garcia Gea, Estela
  • Rosales Ortiz, Silvia Karina
  • Soler Artigas, Maria
  • Ribases Haro, Marta
  • Ramos-Quiroga, Josep Antoni
TDAH; Comunitat científica, TDAH; Comunidad científica, ADHD; Scientific community, Compelling evidence supports alterations in gut microbial diversity, bacterial composition, and/or relative abundance of several bacterial taxa in attention-deficit/hyperactivity disorder (ADHD). However, findings for ADHD are inconsistent among studies, and specific gut microbiome signatures for the disorder remain unknown. Given that previous studies have mainly focused on the pediatric form of the disorder and involved small sample sizes, we conducted the largest study to date to compare the gastrointestinal microbiome composition in 100 medication-naïve adults with ADHD and 100 sex-matched healthy controls. We found evidence that ADHD subjects have differences in the relative abundance of several microbial taxa. At the family level, our data support a lower relative abundance of Gracilibacteraceae and higher levels of Selenomonadaceae and Veillonellaceae in adults with ADHD. In addition, the ADHD group showed higher levels of Dialister and Megamonas and lower abundance of Anaerotaenia and Gracilibacter at the genus level. All four selected genera explained 15% of the variance of ADHD, and this microbial signature achieved an overall sensitivity of 74% and a specificity of 71% for distinguishing between ADHD patients and healthy controls. We also tested whether the selected genera correlate with age, body mass index (BMI), or scores of the ADHD rating scale but found no evidence of correlation between genera relative abundance and any of the selected traits. These results are in line with recent studies supporting gut microbiome alterations in neurodevelopment disorders, but further studies are needed to elucidate the role of the gut microbiota on the ADHD across the lifespan and its contribution to the persistence of the disorder from childhood to adulthood.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

New candidate blood biomarkers potentially associated with white matter hyperintensities progression

  • Jimenez Balado, Joan
  • Pizarro Gonzálvez, Jesús
  • Riba Llena, Yolanda
  • Penalba Morenilla, Anna
  • Faura Llorens, Julia
  • Pala Vila, Elena
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
  • Delgado Martínez, Maria Pilar
Barrera hematoencefàlica; Interaccions neurovasculars; Neurociència, Barrera hematoencefálica; Interacciones neurovasculares; Neurociencia, Blood-brain barrier; Neuro-vascular interactions; Neuroscience, We aimed to discover blood biomarkers associated with longitudinal changes in white matter hyperintensities (WMH). This study was divided into a discovery phase and a replication phase. Subjects in both studies were patients with hypertension, aged 50-70, who underwent two magnetic resonance imaging (MRI) sessions and blood extractions over a 4-year follow-up period. In the discovery phase, we screened 1305 proteins in 12 subjects with WMH progression and in 12 matched control subjects. We found that 41 proteins were differentially expressed: 13 were upregulated and 28 were downregulated. We subsequently selected three biomarkers for replication in baseline and follow-up samples in 80 subjects with WMH progression and in 80 control subjects. The selected protein candidates for the replication were MMP9 (matrix metalloproteinase-9), which was higher in cases, MET (hepatocyte growth factor receptor) and ASAH2 (neutral ceramidase), which were both lower in cases of WMH progression. Baseline biomarker concentrations did not predict WMH progression. In contrast, patients with WMH progression presented a steeper decline in MET over time. Furthermore, cases showed higher MMP9 and lower ASAH2 levels than controls at the follow-up. These results indicate that MMP9, MET, and ASAH2 are potentially associated with the progression of WMH, and could therefore be interesting candidates to validate in future studies., Funds were obtained from the Instituto de Salud Carlos III (Grant Numbers: PI14/01535, PI17/02222, ICI14/307, PI19/00217, CP15/00010, and JR15/00032), incorporation of scientists and technicians to research groups (PERIS, SLT006/17/00266) and the AGAUR (FI_DGR 2017, Grant Number 2017_FI_B 00064), with the support of the Secretary of Universities and Research (Department of Economy and Knowledge, Generalitat de Catalunya), and was cofinanced by the European Regional Development Fund. The neurovascular research laboratory receives funds from the Spanish research stroke network (RD/16/0019/0021).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The negative impact of neurodevelopmental disorders and multiple co-occurring conditions on academic performance of school-age children and adolescents

  • Autet, Aurea
  • Pagespetit, Èlia
  • Andreu, Maria
  • Pagerols, Mireia
  • Prat, Raquel
  • Español Martin, Gemma
Academic performance; Co-occurring conditions; Neurodevelopmental disorders, Rendiment acadèmic; Condicions concurrents; Trastorns del neurodesenvolupament, Rendimiento académico; Condiciones concurrentes; Trastornos del neurodesarrollo, Students with neurodevelopmental disorders (ND) are at risk for academic impairment. However, the pervasive co-occurrence among these conditions has rarely been considered when evaluating this association. This study examined whether intellectual disabilities (ID), communication disorders, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), specific learning disorder (SLD), and motor disorders were related to academic outcomes. Parents and teachers completed standardized screening instruments for mental health problems and learning difficulties. Children who screened positive were interviewed for diagnostic confirmation according to the Diagnostic and Statistical Manual of Mental Disorders, while students who screened negative served as controls. Academic performance across multiple subjects was obtained from school records. The final sample comprised 9018 participants aged 5-17. Mixed-effects ordinal logistic regression models determined the independent and combined effects of ND on academic performance, adjusting for background and coexisting conditions. When examined separately, each diagnostic category was significantly associated with lower marks in all educational outcomes, even after adjusting for sociodemographic and school-related factors. However, when the influence of neurodevelopmental co-occurrence was controlled for, ID emerged as the strongest predictor of poor academic performance, followed by ADHD, SLD, and communication disorders. ASD and motor disorders were only associated with lower marks in arts and physical education. Furthermore, youth with coexisting conditions were at higher risk for academic impairment across all subjects. These findings highlight the need for early diagnosis and targeted interventions to address the specific educational needs of students with ND. Likewise, co-occurring diagnoses should be actively sought to avoid disadvantaging children with multiple disorders., This work was funded by Fundació “la Caixa” (LCR/PR/PR20/51150021), Diputació de Barcelona (PR(AG)72-2012 (2016/011627)), Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00285), Fundació La Marató de TV3 (202228-30-31), Fondo de Investigaciones Sanitarias (PI23/00026, PI23/00040), Agència de Gestió d’Ajuts Universitaris i de Recerca (DI-2024-00034), Fundació d’Investigació Salut i Progrés (FISP), and the Department of Health (Generalitat de Catalunya).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

  • Clougher, Derek
  • Mezquida Mateos, Gisela
  • Sánchez-Torres, Ana Maria
  • Serra-Navarro, Maria
  • Penadés , Rafael
  • Forte, Maria Florencia
  • Amoretti, Silvia
  • Ramos-Quiroga, Josep Antoni
Emotional intelligence; Emotional processing; Neurocognition, Inteligencia emocional; Procesamiento emocional; Neurocognición, Intel·ligència emocional; Processament emocional; Neurocognició, Emotional intelligence (EI) and neurocognition (NC) impairments are common in first-episode psychosis (FEP), yet their evolution over time remains unclear. This study identified patient profiles in EI and NC performance in FEP. 98 adult FEP patients and 128 healthy controls (HCs) were tested on clinical, functional, EI, and NC variables at baseline and two-year follow-up (FUP). A repeated-measures ANOVA compared the effects of group (patients and HCs) and time on EI. Significant EI improvements were observed in both groups. Four groups were created based on NC and EI performance at baseline and FUP in patients: impairment in NC and EI, impairment in NC only, impairment in EI only, and no impairment. At FUP, patients impaired in NC and EI showed less cognitive reserve (CR), greater negative and positive symptoms, and poorer functional outcomes. At FUP, three group trajectories were identified: (I) maintain dual impairment (II) maintain no impairment or improve, (III) maintain sole impairment or worsen. The maintain dual impairment group had the lowest levels of CR. EI and NC impairments progress differently in FEP. Greater CR may protect against comorbid EI/NC impairment. Identifying these patient characteristics could contribute to the development of personalised interventions., This study is part of a coordinated-multicentre Project, funded by the Ministerio de Economía y Competitividad (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, by the CERCA Programme / Generalitat de Catalunya AND Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2021 SGR 01120). Departament de Salut de la Generalitat de Catalunya, en la convocatòria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. This work was supported by La Marató-TV3 Foundation grants 202234-30 (to E. Vieta), 202234-32 (to S. Amoretti). S. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future”. MFF received the support of “Contratos predoctorales de formación en investigación en salud" (PFIS22) (FI22/00185) from the Instituto de Salud Carlos III (ISCIII) with European funds from the Recovery, Transformation and Resilience Plan, by virtue of the Resolution of the Directorate of the Carlos III Health Institute, O.A., M.P. of December 14, 2022, granting Predoctoral Research Training Contracts in Health (PFIS Contracts). Funded by the European Union – tGenerationEU. E. Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI18/00805; PI21/00787) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2021 SGR 1358) and the project SLT006/17/00357, from PERIS 2016-2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. A. González-Pinto thanks the support of the Spanish Ministry of Science, Innovation and Universities PI21/00713, PI18/01055 integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Basque Government 2022111054. C. Torrent thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI20/00344) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Functioning assessment short test (FAST): validity and reliability in adults with Autism Spectrum Disorder

  • Gisbert Gustemps, Laura
  • Lugo Marin, Jorge
  • Español Martín, Gemma
  • Bonnín, C. Mar
  • Vieta, Eduard
  • Setien Ramos, Imanol
  • Ramos-Quiroga, Josep Antoni
Quocient de l'espectre de l'autisme; Anàlisi factorial; Fiabilitat, Cociente del espectro autista; Análisis factorial; Fiabilidad, Autism Spectrum quotient; Factor analysis; Reliability, Background The assessment of functional impairment is crucial both for the diagnosis and the therapeutic approach to autism spectrum disorder (ASD). The purpose of the present study was to evaluate whether the FAST is a reliable and valid tool to assess functional impairment in adults with Level 1 ASD and to study the differences in psychosocial functioning between younger and older adults with ASD. Methods A case–control study was carried out in a sample of 150 participants, 71 adults with Level 1 ASD, and 79 adults without psychiatric history records. Results Results showed good psychometric properties in terms of validity and reliability. Cronbach’s alpha for the total scale was .91 and the area under the curve was .98. The study also showed that adults with ASD present different profiles of functional impairment depending on their age: while younger patients present greater impairment in autonomy, older patients show more difficulties in interpersonal relationships. Conclusions Our results support the use of the FAST in the evaluation of adaptive functioning in adults with Level 1 ASD., The author ISR is currently funded by the Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT006/17/00287) and Instituto de Salud Carlos III (PI18/01788). The funders played no part in study design, collection, management, and interpretation of the data; writing the report; or the decision to submit the report for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Dissecting the polygenic contribution of attention-deficit/hyperactivity disorder and autism spectrum disorder on school performance by their relationship with educational attainment

  • Bosch, Rosa
  • Carabí-Gassol, Pau
  • MACÍAS CHIMBORAZO, VALERIA
  • Español Martin, Gemma
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Attention-deficit/hyperactivity disorder; Autism spectrum disorder; School performance, Trastorn per dèficit d'atenció i hiperactivitat; Trastorn de l'espectre autista; Rendiment escolar, Trastorno por déficit de atención e hiperactividad; Trastorno del espectro autista; Rendimiento escolar, Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are strongly associated with educational attainment (EA), but little is known about their genetic relationship with school performance and whether these links are explained, in part, by the genetic liability of EA. Here, we aim to dissect the polygenic contribution of ADHD and ASD to school performance, early manifestation of psychopathology and other psychiatric disorders and related traits by their relationship with EA. To do so, we tested the association of polygenic scores for EA, ADHD and ASD with school performance, assessed whether the contribution of the genetic liability of ADHD and ASD to school performance is influenced by the genetic liability of EA, and evaluated the role of EA in the genetic overlap between ADHD and ASD with early manifestation of psychopathology and other psychiatric disorders and related traits in a sample of 4,278 school-age children. The genetic liability for ADHD and ASD dissected by their relationship with EA show differences in their association with school performance and early manifestation of psychopathology, partly mediated by ADHD and ASD symptoms. Genetic variation with concordant effects in ASD and EA contributes to better school performance, while the genetic variation with discordant effects in ADHD or ASD and EA is associated with poor school performance and higher rates of emotional and behavioral problems. Our results strongly support the usage of the genetic load for EA to dissect the genetic and phenotypic heterogeneity of ADHD and ASD, which could help to fill the gap of knowledge of mechanisms underlying educational outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404, PI23/00026 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Network Center for Biomedical Research (CIBER) to J.C.D.; the European Regional Development Fund (ERDF); the ECNP Network ‘ADHD across the Lifespan’; “la Marató de TV3” (202228-30 and 202228-31), “Fundació ‘la Caixa’, Diputació de Barcelona, Pla Estratègic de Recerca i Innovació en Salut” (PERISSLT006/17/285); “Fundació Privada d’Investigació Sant Pau” (FISP); and Ministry of Health of Generalitat de Catalunya.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide

  • Camara Sanchez, Patricia
  • Garcia Aranda, Natalia
  • Gener, Petra
  • Seras Franzoso, Joaquin
  • Giani Alonso, Micaela
  • Schwartz Navarro, Simon
  • Abasolo Olaortua, Ibane
  • Diaz Riascos, Zamira Vanessa
Cancer stem cells; Combination therapy; Niclosamide, Células madre cancerosas; Terapia combinada; Niclosamida, Cèl·lules mare cancerígenes; Teràpia combinada; Niclosamida, Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. Here, we aimed to identify potential drugs targeting CSCs to be further employed in combination with standard chemotherapy in TNBC treatment. The anti-CSC efficacy of up to 17 small drugs was tested in TNBC cell lines using cell viability assays on differentiated cancer cells and CSCs. Then, the effect of 2 selected drugs (8-quinolinol -8Q- and niclosamide -NCS-) in the cancer stemness features were evaluated using mammosphere growth, cell invasion, migration and anchorage-independent growth assays. Changes in the expression of stemness genes after 8Q or NCS treatment were also evaluated. Moreover, the potential synergism of 8Q and NCS with PTX on CSC proliferation and stemness-related signaling pathways was evaluated using TNBC cell lines, CSC-reporter sublines, and CSC-enriched mammospheres. Finally, the efficacy of NCS in combination with PTX was analyzed in vivo using an orthotopic mouse model of MDA-MB-231 cells. Among all tested drug candidates, 8Q and NCS showed remarkable specific anti-CSC activity in terms of CSC viability, migration, invasion and anchorage independent growth reduction in vitro. Moreover, specific 8Q/PTX and NCS/PTX ratios at which both drugs displayed a synergistic effect in different TNBC cell lines were identified. The sole use of PTX increased the relative presence of CSCs in TNBC cells, whereas the combination of 8Q and NCS counteracted this pro-CSC activity of PTX while significantly reducing cell viability. In vivo, the combination of NCS with PTX reduced tumor growth and limited the dissemination of the disease by reducing circulating tumor cells and the incidence of lung metastasis. The combination of 8Q and NCS with PTX at established ratios inhibits both the proliferation of differentiated cancer cells and the viability of CSCs, paving the way for more efficacious TNBC treatments., This work was supported by the Instituto de Salud Carlos III (ISCiii), through Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), an initiative that also counts with the assistance from the European Regional Development Fund (ERDF), specifically in the PENTRI-2 Project and by the “Fundació Marató TV3” (337/C/2013) to I.A., M.R. and E.V. Our laboratories were also supported by the Fondo de Investigaciones Sanitarias (FIS, grants PI20/1474 to S.S.J. and PI18/00871 and PI21/00936), co-financed by the ERDF and the 2017-SGR-638 of the Catalan Government to S.S.J. and EvoNano Project (GA800983), funded by European Union’s Horizon 2020 FET Open Programme. N.G.-A. was supported by grants from Pla Estratègic de Recerca i Innovació en Salut (PERIS) of Catalonia (SLT006/17/00270 270).
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Identifying social cognition subgroups in euthymic patients with bipolar disorder: a cluster analytical approach

  • Varo, Cristina
  • Solé, Brisa
  • Jiménez, Esther
  • Bonnin, Caterina del Mar
  • Torrent, Carla
  • Valls, Elia
  • Lahera Forteza, Guillermo
  • Martínez Arán, Anabel
  • Carvalho, Andre F.
  • Miskowiak, Kamilla W.
  • Vieta, Eduard
  • Reinares, María
Background. Bipolar disorder (BD) is associated with social cognition (SC) impairments even during remission periods although a large heterogeneity has been described. Our aim was to explore the existence of different profiles on SC in euthymic patients with BD, and further explore the potential impact of distinct variables on SC. Methods. Hierarchical cluster analysis was conducted using three SC domains [Theory of Mind (ToM), Emotional Intelligence (EI) and Attributional Bias (AB)]. The sample comprised of 131 individuals, 71 patients with BD and 60 healthy control subjects who were compared in terms of SC performance, demographic, clinical, and neurocognitive variables. A logistic regression model was used to estimate the effect of SC-associated risk factors. Results. A two-cluster solution was identified with an adjusted-performance group (N = 48, 67.6%) and a low-performance group (N = 23, 32.4%) with mild deficits in ToM and AB domains and with moderate difficulties in EI. Patients with low SC performance were mostly males, showed lower estimated IQ, higher subthreshold depressive symptoms, longer illness duration, and poorer visual memory and attention. Low estimated IQ (OR 0.920, 95% CI 0.863–0.981), male gender (OR 5.661, 95% CI 1.473–21.762), and longer illness duration (OR 1.085, 95% CI 1.006–1.171) contributed the most to the patients clustering. The model explained up to 35% of the variance in SC performance. Conclusions. Our results confirmed the existence of two discrete profiles of SC among BD. Nearly two-thirds of patients exhibited adjusted social cognitive abilities. Longer illness duration, male gender, and lower estimated IQ were associated with low SC performance., Instituto de Salud Carlos III, Generalitat de Catalunya